The support of human genetic evidence for approved drug indications.
paper
Cited
Public
Unavailable
- Authors
- Nelson, Matthew R; Tipney, Hannah; Painter, Jeffery L; Shen, Judong; Nicoletti, Paola; Shen, Yufeng; Floratos, Aris; Sham, Pak Chung; Li, Mulin Jun; Wang, Junwen; Cardon, Lon R; Whittaker, John C; Sanseau, Philippe
- Year
- 2015
- Journal
- Nature genetics
- PMID
- 26121088
- DOI
- 10.1038/ng.3314
Over a quarter of drugs that enter clinical development fail because they are ineffective. Growing insight into genes that influence human disease may affect how drug targets and indications are selected. However, there is little guidance about how much weight should be given to genetic evidence in making these key decisions. To answer this question, we investigated how well the current archive of genetic evidence predicts drug mechanisms. We found that, among well-studied indications, the proportion of drug mechanisms with direct genetic support increases significantly across the drug development pipeline, from 2.0% at the preclinical stage to 8.2% among mechanisms for approved drugs, and varies dramatically among disease areas. We estimate that selecting genetically supported targets could double the success rate in clinical development. Therefore, using the growing wealth of human genetic data to select the best targets and indications should have a measurable impact on the successful development of new drugs.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes. | Zhong X et al. | β | 2026 | β |
| A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis. | Giordano A et al. | β | 2026 | β |
| A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation. | Balakumar P et al. | β | 2026 | β |
| A potential drug target in epilepsy and its role in other neurological disorders. | Gao S et al. | β | 2026 | β |
| Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision. | Furukawa S et al. | β | 2026 | β |
| A small lipidated peptide targeting Na<sub>V</sub>1.8 channels attenuates osteoarthritic pain behavior and prevents bone erosion. | Rodriguez R et al. | β | 2026 | β |
| Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation. | Poppelaars F et al. | β | 2026 | β |
| CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer. | Shi W et al. | β | 2026 | β |
| Deciphering tissue-specific protein regulation for insights into cardiometabolic disease. | Hartley AE et al. | β | 2026 | β |
| Dissecting the genetic and proteomic risk factors for delirium. | Raptis V et al. | β | 2026 | β |
| Druggable targets and immunological mechanisms for type 1 diabetes treatment: Genetic evidence from multi-omics Mendelian randomization combined with meta-analysis. | Mei X et al. | β | 2026 | β |
| Endothelial TRIM47 regulates blood-brain barrier integrity and cognition via the KEAP1/NRF2 signalling pathway in mice. | Delobel V et al. | β | 2026 | β |
| Expression-driven genetic dependency reveals targets for precision oncology. | Elmas A et al. | β | 2026 | β |
| Genetic Association of Circulating Proteins and Gene Transcripts With Spontaneous Coronary Artery Dissection. | Ardissino M et al. | β | 2026 | β |
| Genotype-driven variations in lncRNA expression underlie predisposition to high-grade serous ovarian cancer. | Lu M et al. | β | 2026 | β |
| Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activity. | Rush JS et al. | β | 2026 | β |
| Identification of potential drug targets for delirium from genetic insights: A Mendelian randomization study. | Geng YN et al. | β | 2026 | β |
| Identification of potential drug targets for erectile dysfunction with single-cell RNA sequencing: A Mendelian randomization study. | Xiang BY et al. | β | 2026 | β |
| Identification of potential therapeutic targets for stroke and its subtypes by integrating proteomes and genetics from human plasma. | Liu H et al. | β | 2026 | β |
| Identifying drug targets for schizophrenia through gene prioritization. | Kraft J et al. | β | 2026 | β |
| Identifying potential drug targets for seborrhoeic dermatitis and dry eye syndrome through mendelian randomisation analysis. | Zuo H et al. | β | 2026 | β |
| Identifying potential therapeutic targets in periodontitis: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization. | Zhou H et al. | β | 2026 | β |
| Integrative functional genomics analysis identifies pleiotropic genes for vascular diseases. | Solomon CU et al. | β | 2026 | β |
| Integrative Human Genomic and Pharmacological Analyses Identify CACNB4 as a Druggable Target for Periodontitis. | Jiang Y et al. | β | 2026 | β |
| Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention. | Li Q et al. | β | 2026 | β |
| Leveraging large-scale biobanks for therapeutic target discovery. | Ferolito BR et al. | β | 2026 | β |
| Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds. | Parker N et al. | β | 2026 | β |
| Lipoprotein(a) and Abdominal Aortic Aneurysm: A Genetically Verified Target Meets a Clinical Translational Window. | Lee R | β | 2026 | β |
| Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes. | Zou XZ et al. | β | 2026 | β |
| Potential Risk Factors and Therapeutic Targets for Dilated Cardiomyopathy Identified Through Mendelian Randomization Analysis. | Wang H et al. | β | 2026 | β |
| Proteome-Guided Drug Target Discovery for Periodontitis. | Alayash Z et al. | β | 2026 | β |
| RAB3GAP2 is a regulator of skeletal muscle endothelial cell proliferation and associated with capillary-to-fiber ratio. | StrΓΆm K et al. | β | 2026 | β |
| Robust human genetic evidence supporting causal effects of FGF21 on reducing alcohol consuming behaviours. | CronjΓ© HT et al. | β | 2026 | β |
| Safetyome and specialized panels for over 3,000 phenotypes: a systematic and translational approach using human genetics and pharmacology. | Liu X et al. | β | 2026 | β |
| scVMAP: a comprehensive platform for integrating single-cell chromatin accessibility regions with causal variants. | Yu ZM et al. | β | 2026 | β |
| The brain imaging feature-related gene NRP2 drives the malignant progression of glioblastoma through the FAK pathway: a Mendelian randomization study. | Li Y et al. | β | 2026 | β |
| The gene expression landscape of disease genes. | GarcΓa-GonzΓ‘lez J et al. | β | 2026 | β |
| The genetics of hypertension. | StΓΆlting G et al. | β | 2026 | β |
| The Inherited Basis of Coronary Artery Disease. | Schunkert H et al. | β | 2026 | β |
| Therapeutic targeting of neuroimmune mechanisms in neurodegeneration. | Monroe KM et al. | β | 2026 | β |
| The shared genetic architecture underlying the autoimmune and cardiovascular disease: a multivariate genome-wide analysis. | Zhang J et al. | β | 2026 | β |
| Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies. | Namuli KL et al. | β | 2026 | β |
| A Career Doing STUFF. | Hann MM | β | 2025 | β |
| A cis-regulatory element controls expression of histone deacetylase 9 to fine-tune inflammasome-dependent chronic inflammation in atherosclerosis. | Asare Y et al. | β | 2025 | β |
| A comparison of computational methods for expression forecasting. | Kernfeld E et al. | β | 2025 | β |
| Advances in Computational Drug Repurposing, Driver Genes, and Therapeutics in Lung Adenocarcinoma. | Nematzadeh S et al. | β | 2025 | β |
| A genome-wide CRISPR screen identifies the TNRC18 gene locus as a regulator of inflammatory signaling. | Rahimov F et al. | β | 2025 | β |
| A multi-omics Mendelian randomization study identifies new therapeutic targets for alcohol use disorder and problem drinking. | Rosoff DB et al. | β | 2025 | β |
| A multi-omics Mendelian randomization study reveals PAM as a potential therapeutic target for type 2 diabetes. | Yi M et al. | β | 2025 | β |
| A multi-omics target study for glioblastoma multiforme (GBM) based on Mendelian randomization analysis. | Sun H et al. | β | 2025 | β |
| Analyses of GWAS and Sub-Threshold Loci Lead to the Discovery of Dendrite Development and Morphology Dysfunction Underlying Schizophrenia Genetic Risk. | Chen R et al. | β | 2025 | β |
| An atlas of single-cell eQTLs dissects autoimmune disease genes and identifies novel drug classes for treatment. | Wang L et al. | β | 2025 | β |
| An in-depth review of AI-powered advancements in cancer drug discovery. | Le MHN et al. | β | 2025 | β |
| An Ocular Gene-Set Expression Library for Heritability Partition and Cell Line Enrichment Analyses. | Hysi PG et al. | β | 2025 | β |
| A Novel Statistical Method for Unmasking Sex-Specific Genomics Signatures in Complex Traits. | Mansouri S et al. | β | 2025 | β |
| (Apo)Lipoprotein Profiling with Multi-Omics Analysis Identified Medium-HDL-Targeting PSRC1 with Therapeutic Potential for Coronary Artery Disease. | Li Y et al. | β | 2025 | β |
| Association between antidiabetic drug targets and psychiatric disorders. | Yuan R et al. | β | 2025 | β |
| Associations between human blood metabolome and vascular dementia. | Jia Y et al. | β | 2025 | β |
| Atlas of the plasma proteome in health and disease in 53,026 adults. | Deng YT et al. | β | 2025 | β |
| A Transcriptome-Wide Mendelian Randomization Study in Isolated Human Immune Cells Highlights Risk Genes Involved in Viral Infections and Potential Drug Repurposing Opportunities for Schizophrenia. | Stacey D et al. | β | 2025 | β |
| Beyond Bone Loss: A Biology Perspective on Osteoporosis Pathogenesis, Multi-Omics Approaches, and Interconnected Mechanisms. | Zhao Y et al. | β | 2025 | β |
| Brain and blood transcriptome-wide association studies identify five novel genes associated with Alzheimer's disease. | Mews MA et al. | β | 2025 | β |
| Brain-heart-eye axis revealed by multi-organ imaging genetics and proteomics. | MULTI Consortium et al. | β | 2025 | β |
| Building a human genetic data lake to scale up insights for drug discovery. | Chatelain C et al. | β | 2025 | β |
| Can AI reveal the next generation of high-impact bone genomics targets? | Greene CS et al. | β | 2025 | β |
| Causal Associations Between 141 Gut Microbiota Taxa and 14 Rheumatic Diseases: A Mendelian Randomization Study. | Hu Y et al. | β | 2025 | β |
| Causal associations between circulating metabolites and chronic kidney disease: a Mendelian randomization study. | He J et al. | β | 2025 | β |
| Causal Inference and Annotation of Phosphoproteomics Data in Multiomics Cancer Studies. | Dong Q et al. | β | 2025 | β |
| Cholesterol-lowering drug targets reduce risk of dementia: Mendelian randomization and meta-analyses of 1 million individuals. | Nordestgaard LT et al. | β | 2025 | β |
| Combining computational target prioritization and a B cell maturation assay for target evaluation studies in systemic lupus erythematosus. | Shang MM et al. | β | 2025 | β |
| Combining Single-Cell RNA Sequencing and Mendelian Randomization to Explore Novel Drug Targets for Parkinson's Disease. | Wu X et al. | β | 2025 | β |
| Context-specific eQTLs provide deeper insight into causal genes underlying shared genetic architecture of COVID-19 and idiopathic pulmonary fibrosis. | Dalapati T et al. | β | 2025 | β |
| DBI Mediates the Progression of Ankylosing Spondylitis by Regulating CD56<sup>dim</sup> NK Cells Cytotoxicity Function. | Zhao R et al. | β | 2025 | β |
| Decoding the Therapeutic Target SVEP1: Harnessing Molecular Trait GWASs to Unravel Mechanisms of Human Disease. | Elenbaas JS et al. | β | 2025 | β |
| Discovering genetically-supported drug targets for multisite chronic pain through multi-omics Mendelian randomization and single-cell RNA-sequencing. | Cui Z et al. | β | 2025 | β |
| Dissecting causal relationships between immune cells, blood metabolites, and diabetic nephropathy. | Zheng S et al. | β | 2025 | β |
| Diverse ancestral representation improves genetic intolerance metrics. | Han AL et al. | β | 2025 | β |
| Druggable Genome Mendelian Randomization and GWAS-sceQTLs MR Analysis Reveal Genetic Associations Between Open-Angle Glaucoma and Immune Cells, and Identify Potential Drugs. | Ke K et al. | β | 2025 | β |
| Druggable Genome-Wide Mendelian Randomization Identifies Distinct Therapeutic Targets for Low Back Pain, Intervertebral Disk Degeneration, and Sciatica. | Sun A et al. | β | 2025 | β |
| Druggable Targets for Pelvic Inflammatory Disease: Mendelian Randomization and Experimental Validation. | Dang C et al. | β | 2025 | β |
| Drug repurposing opportunities for breast cancer and seven common subtypes. | Lin Y et al. | β | 2025 | β |
| Endothelial Cells Increase Mesenchymal Stem Cell Differentiation in Scaffold-Free 3D Vascular Tissue. | DeMaria WG et al. | β | 2025 | β |
| Estrogen receptor Ξ² deficiency increases the susceptibility to ulcerative colitis by inducing mitochondrial fission and consequently accelerating senescence of colonic epithelial cells. | Guo Y et al. | β | 2025 | β |
| Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology. | Xu Y et al. | β | 2025 | β |
| Exploring therapeutic targets for hepatocellular carcinoma through druggable genes. | Tang C et al. | β | 2025 | β |
| Exploring upstream and downstream causality of inflammatory cytokines in intervertebral disc degeneration: a bidirectional, two-sample Mendelian randomization study. | Huang P et al. | β | 2025 | β |
| Focusing on spinal stenosis: emerging discoveries concerning Alendronate-induced risks and genetic drug targets. | Yang N et al. | β | 2025 | β |
| From clock to clock: Therapeutic target discovery for aging and age-related diseases. | Chen J et al. | β | 2025 | β |
| From variants to mechanisms: Neurogenomics in the post-GWAS era. | Margolis MP et al. | β | 2025 | β |
| Functional analysis of cancer-associated germline risk variants. | Kellman LN et al. | β | 2025 | β |
| Functional and Practical Insights Into the Genetic Basis of Takayasu Arteritis. | Casares-Marfil D et al. | β | 2025 | β |
| Genetic evidence informs the direction of therapeutic modulation in drug development. | Chen R et al. | β | 2025 | β |
| Genetic Exploration of Targeting the Transient Receptor Potential Cation Channel Subfamily Member 6. | Graesser C et al. | β | 2025 | β |
| Genetic insights into drug targets for alzheimer's disease: integrative multi-omics analysis. | Liu X et al. | β | 2025 | β |
| Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study. | Cao Y et al. | β | 2025 | β |
| Genetic profiling of the circulating proteome in common diseases suggests causal proteins and improves risk prediction. | Ma Q et al. | β | 2025 | β |
| Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease. | Pei Y et al. | β | 2025 | β |
| Genetic Risk Score Enables a Vaccine for Early Primary Prevention of CAD. | Roberts R | β | 2025 | β |
| Genome-wide association study and polygenic risk prediction of hypothyroidism. | Rand SA et al. | β | 2025 | β |
| Genome-wide association study of susceptibility to acute respiratory distress syndrome. | Guillen-Guio B et al. | β | 2025 | β |
| Genomic and GEO data integration identifies PDGFB as a potential therapeutic target for sepsis. | Guo M et al. | β | 2025 | β |
| Genomic characterization of Huntington's disease genetic modifiers informs drug target tractability. | Namuli KL et al. | β | 2025 | β |
| Genomic data-driven framework for drug target discovery in atrial fibrillation. | Tao Y et al. | β | 2025 | β |
| Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients. | Alghubayshi A et al. | β | 2025 | β |
| Geroscience in heart failure: the search for therapeutic targets in the shared pathobiology of human aging and heart failure. | Castro C et al. | β | 2025 | β |
| Glucokinase Regulatory Protein as a Putative Target for Gestational Diabetes Mellitus and Related Complications: Evidence From the Mendelian Randomization Study. | Mao W et al. | β | 2025 | β |
| GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. | Dand N et al. | β | 2025 | β |
| HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke. | Lin H et al. | β | 2025 | β |
| Hope vs Hype II: We should stop embarking on epidemiology-based disease modifying clinical trials. | Espay AJ et al. | β | 2025 | β |
| Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study. | deGoma E et al. | β | 2025 | β |
| Hypertension precision medicine: the promise and pitfalls of pharmacogenomics. | Le NN et al. | β | 2025 | β |
| Identification and validation of five novel protein targets for type 2 diabetes mellitus. | Tao M et al. | β | 2025 | β |
| Identification of biomarkers and potential drug targets for esophageal cancer: a Mendelian randomization study. | Li C et al. | β | 2025 | β |
| Identification of circulating inflammatory proteins as potential drug targets for sepsis through Mendelian randomization and colocalization analyses. | Wan F et al. | β | 2025 | β |
| Identification of Co-Diagnostic Genes and Potential Therapeutic Targets for Asthma and Sepsis Through Mendelian Randomization and Immune Infiltration Analysis. | Chen C et al. | β | 2025 | β |
| Identification of genetically-supported new drug targets for osteomyelitis based on druggable genomes. | Yao R et al. | β | 2025 | β |
| Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking. | Bi C et al. | β | 2025 | β |
| Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome. | Yun Z et al. | β | 2025 | β |
| Identification of potential drug targets for pelvic organ prolapse using a proteome-wide Mendelian randomization approach. | Xie Z et al. | β | 2025 | β |
| Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study. | Wang S et al. | β | 2025 | β |
| Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases. | Stratford JK et al. | β | 2025 | β |
| Immune cell-based transcriptomic Mendelian randomization and colocalization study on type 1 diabetes. | Sklar J et al. | β | 2025 | β |
| Improved Annotation of Asthma Gene Variants with Cell Type Deconvolution of Nasal and Lung Expression Quantitative Trait Loci. | El-Husseini ZW et al. | β | 2025 | β |
| Integrated analysis for drug repositioning in migraine using genetic evidence and claims database. | Inokuchi S et al. | β | 2025 | β |
| Integrated summary data-based Mendelian randomization and colocalization analysis reveals TNNT3 as a target of Deer-Antler-Ginseng-formula for triple-negative breast cancer. | Jia J et al. | β | 2025 | β |
| Integrating Expression Quantitative Trait Loci and Genome-Wide Association Study Identifies Druggable Genes for Tinnitus. | Guo T et al. | β | 2025 | β |
| Integrating Human Proteomes with Genome-Wide Association Data Reveals Prioritized Therapeutic Candidates for Lung Squamous Cell Carcinoma. | Zhang Y et al. | β | 2025 | β |
| Integrating -Omic Technologies across Modality, Space, and Time to Decipher Remodeling in Cardiac Disease. | Mulvey JF et al. | β | 2025 | β |
| Integrating single-cell RNA sequencing and Mendelian randomization analysis to identify potential drug targets for dilated cardiomyopathy. | Liu R et al. | β | 2025 | β |
| Integrating Single-Cell Transcriptome-Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune-Related Drug Targets for Cancers. | Zheng J et al. | β | 2025 | β |
| Integrative Analysis of Plasma Proteomics and Transcriptomics Reveals Potential Therapeutic Targets for Psoriasis. | Wang H et al. | β | 2025 | β |
| Integrative analysis reveals synergistic regulation of Sp7 by BRD9 and Wnt/Ξ²-catenin signaling during osteogenic differentiation. | Wu L et al. | β | 2025 | β |
| Integrative genomic and single-cell framework identifies druggable targets for colorectal cancer precision therapy. | Hong Y et al. | β | 2025 | β |
| Intestinal anti-inflammatory drug targets as potential modifiers of cardiovascular disease risk. | Tong S et al. | β | 2025 | β |
| Intracellular trafficking SNARE protein, syntaxin-6, modifies prion cellular phenotypes and risk of disease development in vivo. | Hill E et al. | β | 2025 | β |
| Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study. | Zhang H et al. | β | 2025 | β |
| Large language models for drug discovery and development. | Zheng Y et al. | β | 2025 | β |
| Large-scale multi-trait genome-wide analysis for inflammatory bowel disease reveals new insights into its molecular mechanisms and emphasizes the roles of systemic immune regulation. | Zhu Z et al. | β | 2025 | β |
| LazyNet: Interpretable ODE Modeling of Sparse CRISPR Single-Cell Screens Reveals New Biological Insights. | Yi Z et al. | β | 2025 | β |
| Leveraging molecular-QTL co-association to predict novel disease-associated genetic loci using a graph convolutional neural network. | Ng-Kee-Kwong J et al. | β | 2025 | β |
| Leveraging pleiotropy for the improved treatment of psychiatric disorders. | Woodward DJ et al. | β | 2025 | β |
| Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders. | Arnatkeviciute A et al. | β | 2025 | β |
| Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH. | Zhang J et al. | β | 2025 | β |
| <i>DBI</i> as a Novel Immunotherapeutic Candidate in Colorectal Cancer: Dissecting Genetic Risk and the Immune Landscape via GWAS, eQTL, and pQTL. | Tian T et al. | β | 2025 | β |
| Mapping the developmental path for Parkinson's disease therapeutics. | Dhruv NT et al. | β | 2025 | β |
| Mendelian randomization analysis reveals the potential of the IKZF1 gene as a therapeutic target in colorectal cancer. | Lin J et al. | β | 2025 | β |
| Meta-analysis and in-silico functional characterization of the SNCA variant rs356220 in Parkinson's disease. | Menon S et al. | β | 2025 | β |
| Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies. | Goto H et al. | β | 2025 | β |
| mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes. | Hjelholt AJ et al. | β | 2025 | β |
| Multi-dimensional annotation of porcine variants using genomic and epigenomic features in pigs. | Yin H et al. | β | 2025 | β |
| Multi-Omic Insight Into the Molecular Networks in the Pathogenesis of Coronary Artery Disease. | Fang Q et al. | β | 2025 | β |
| Multi-Omic Insight Into the Molecular Networks of Mitochondrial Dysfunction in the Pathogenesis of Schizophrenia. | Yu K et al. | β | 2025 | β |
| Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study. | Hu J et al. | β | 2025 | β |
| Multiomics and Systematic Analyses Reveal the Roles of Hemoglobin and the HIF-1 Pathway in Polycystic Ovary Syndrome. | Wang G et al. | β | 2025 | β |
| Multiomic Underpinnings of Drug Targets for Intracranial Aneurysm: Evidence From Diversified Mendelian Randomization. | Fan YX et al. | β | 2025 | β |
| Multi-omic underpinnings of heterogeneous aging across multiple organ systems. | Xiong J et al. | β | 2025 | β |
| Multi-tissue expression and splicing data prioritise anatomical subsite- and sex-specific colorectal cancer susceptibility genes. | Hazelwood E et al. | β | 2025 | β |
| Multivariate genome-wide analyses of insulin resistance unravel novel loci and therapeutic targets for cardiometabolic health. | Ye C et al. | β | 2025 | β |
| Narrowing Down Key Players in Autoimmunity via Single-Cell Multiomics. | Gjurgjaj A et al. | β | 2025 | β |
| Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy. | Wooden B et al. | β | 2025 | β |
| Network-Based Approaches for Drug Target Identification. | Koutsandreas T et al. | β | 2025 | β |
| Novel drug targets for delirium based on genetic causality. | Zhu S et al. | β | 2025 | β |
| Novel therapeutic targets for metabolism-related diseases: proteomic Mendelian randomization and colocalization analyses. | Zhang YY et al. | β | 2025 | β |
| Open Targets: 10 years of partnership in target discovery. | Hulcoop DG et al. | β | 2025 | β |
| Osteoarthritis year in review 2024: Genetics, genomics, and epigenetics. | Boer CG | β | 2025 | β |
| Personalized prediction of anticancer potential of non-oncology drugs through learning from genome derived molecular pathways. | Dong X et al. | β | 2025 | β |
| Pharmacologic and genetic evidence converge on mechanisms of psychotic illness. | Fennessy B et al. | β | 2025 | β |
| Plasma Circulating Proteins and Intracranial Aneurysm Susceptibility: A Proteome-Wide Mendelian Randomization Analysis. | Zou X et al. | β | 2025 | β |
| Polygenic modelling and machine learning approaches in pharmacogenomics: Importance in downstream analysis of genome-wide association study data. | Koido M | β | 2025 | β |
| Potential drug targets for asthma identified through mendelian randomization analysis. | Chen X et al. | β | 2025 | β |
| Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis. | Liu S et al. | β | 2025 | β |
| PRCP is a promising drug target for intracranial aneurysm rupture supported via multi-omics analysis. | Wu J et al. | β | 2025 | β |
| Precision medicine in the pediatric and neonatal intensive care units through genomics. | Duy PQ et al. | β | 2025 | β |
| Prediction of Single-Cell perturbation response based on Direction-Constrained diffusion SchrΓΆdinger Bridge. | Luo Y et al. | β | 2025 | β |
| Prioritization of potential drug targets in ovarian-related diseases: Mendelian randomization and colocalization analyses. | Hong Y | β | 2025 | β |
| Prioritizing Parkinson's disease risk genes in genome-wide association loci. | Lange LM et al. | β | 2025 | β |
| Protein Drug Targets for Abdominal Aortic Aneurysm and Proteomic Associations Between Modifiable Risk Factors and Abdominal Aortic Aneurysm. | Qi Y et al. | β | 2025 | β |
| Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis. | Mulugeta A et al. | β | 2025 | β |
| Proteome-Wide and Immune Cell Phenotype Mendelian Randomization Highlights Immune Involvement in Genetic Generalized Epilepsy. | Gui J et al. | β | 2025 | β |
| Proteome-Wide Mendelian Randomization Identifies Candidate Causal Proteins for Cardiovascular Diseases. | Li C et al. | β | 2025 | β |
| Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease. | Yu K et al. | β | 2025 | β |
| Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma. | Guo Q et al. | β | 2025 | β |
| Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveries. | Hatoum AS et al. | β | 2025 | β |
| RETRACTED: Identification of potential therapeutic targets for breast cancer using Mendelian randomization analysis and drug target prediction. | Huang Z et al. | β | 2025 | β |
| Revealing potential drug targets in schizophrenia through proteome-wide Mendelian randomization genetic insights. | Xie W et al. | β | 2025 | β |
| RUNX2 Phase Separation Mediates Long-Range Regulation Between Osteoporosis-Susceptibility Variant and XCR1 to Promote Osteoblast Differentiation. | Zhang Y et al. | β | 2025 | β |
| Seronegative Sicca Syndrome: Diagnostic Considerations and Management Strategies. | Basheva-Kraeva YM et al. | β | 2025 | β |
| SETD1A regulates psychiatric gene networks involved in genomic stability and synaptic function in rare and sporadic schizophrenia. | Sawada T et al. | β | 2025 | β |
| Single-cell transcriptome-wide Mendelian randomization and colocalization reveals immune-mediated regulatory mechanisms and drug targets for COVID-19. | Ying H et al. | β | 2025 | β |
| Sleep Related Movement Disorders: What's New and Changing Clinical Practice. | Stefani A et al. | β | 2025 | β |
| Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort. | Song X et al. | β | 2025 | β |
| Systematic druggable genome-wide mendelian randomization identifies therapeutic targets for childhood asthma. | Bi J et al. | β | 2025 | β |
| Systematic Mendelian Randomization Exploring Druggable Genes for Hemorrhagic Strokes. | Yang LZ et al. | β | 2025 | β |
| Tackling a disease on a global scale, the Global Parkinson's Genetics Program, GP2: A new generation of opportunities. | Blauwendraat C et al. | β | 2025 | β |
| Temporal trends in evidence supporting novel drug target discovery. | Falaguera MJ et al. | β | 2025 | β |
| The computationally guided design of selective targeters of multiple proteins (STaMPs) as a new opportunity for small molecule drug discovery. | Kaiser TM | β | 2025 | β |
| The evolution of Alzheimer's target identification: Towards a fusion of artificial and cellular intelligence. | Wittenberg G et al. | β | 2025 | β |
| The Hallmarks of Predictive Oncology. | Singhal A et al. | β | 2025 | β |
| The pathogenesis of cerebral small vessel disease and vascular cognitive impairment. | Markus HS et al. | β | 2025 | β |
| The Role of ETS2 in Macrophage Inflammation. | Stankey CT et al. | β | 2025 | β |
| Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy. | SΓ‘nchez-JimΓ©nez P et al. | β | 2025 | β |
| Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine. | Zhang X et al. | β | 2025 | β |
| Unveiling the genetic biomarkers for ageing: evidence from a large sample genome-wide association study and in vivo validation. | Cai Z et al. | β | 2025 | β |
| Using Genomics to Develop Personalized Cardiovascular Treatments. | Sanghvi MM et al. | β | 2025 | β |
| Using human genomics to validate drug targets for acute ischemic stroke. | Heitsch L et al. | β | 2025 | β |
| Whole-genome sequencing of 490,640 UK Biobank participants. | UK Biobank Whole-Genome Sequencing Consortium | β | 2025 | β |
| A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. | Pacini C et al. | β | 2024 | β |
| A cross-disease, pleiotropy-driven approach for therapeutic target prioritization and evaluation. | Bao C et al. | β | 2024 | β |
| A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study. | Liu B et al. | β | 2024 | β |
| A Genome-wide Association Study of Susceptibility to Upper Urinary Tract Infections. | Flatby HM et al. | β | 2024 | β |
| A literature review of genetics and epigenetics of HCV-related hepatocellular carcinoma: translational impact. | Pan Z et al. | β | 2024 | β |
| Analyzing longitudinal trait trajectories using GWAS identifies genetic variants for kidney function decline. | Wiegrebe S et al. | β | 2024 | β |
| Application of Genomic Data in Translational Medicine During the Big Data Era. | Zhang Y et al. | β | 2024 | β |
| Artificial intelligence with mass spectrometry-based multimodal molecular profiling methods for advancing therapeutic discovery of infectious diseases. | Liu J et al. | β | 2024 | β |
| Association between human blood metabolome and the risk of pre-eclampsia. | Ding Y et al. | β | 2024 | β |
| Association between Plasma Brain-derived Neurotrophic Factor Level and Alzheimer's Disease: A Mendelian Randomization Study. | You J et al. | β | 2024 | β |
| A systems biology-based identification and inΒ vivo functional screening of Alzheimer's disease risk genes reveal modulators of memory function. | Hudgins AD et al. | β | 2024 | β |
| Atrial fibrillation variant-to-gene prioritization through cross-ancestry eQTL and single-nucleus multiomic analyses. | Leblanc FJA et al. | β | 2024 | β |
| Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes. | Li H et al. | β | 2024 | β |
| Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease. | Choi DE et al. | β | 2024 | β |
| Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease. | Pengo M et al. | β | 2024 | β |
| Canadian COVID-19 host genetics cohort replicates known severity associations. | Garg E et al. | β | 2024 | β |
| Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test. | Delabays B et al. | β | 2024 | β |
| Causal associations between the insulin-like growth factor family and sarcopenia: a bidirectional Mendelian randomization study. | Liu J et al. | β | 2024 | β |
| Causal effects of plasma metabolites on autoimmune hepatitis (AIH): a bidirectional two-sample mendelian randomization study. | Zheng Z et al. | β | 2024 | β |
| Causal Estimation of Long-term Intervention Cost-effectiveness Using Genetic Instrumental Variables: An Application to Cancer. | Dixon P et al. | β | 2024 | β |
| Challenging Antiplatelet Therapy for Small Vessel Stroke Through Genetics. | Falcone GJ et al. | β | 2024 | β |
| Characterising the genetic architecture of changes in adiposity during adulthood using electronic health records. | Venkatesh SS et al. | β | 2024 | β |
| Common pitfalls in drug target Mendelian randomization and how to avoid them. | Gill D et al. | β | 2024 | β |
| Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach. | Alayash Z et al. | β | 2024 | β |
| Complement C5/C5a in the diagnosis and treatment of Graves<b>'</b> ophthalmopathy: A Mendelian randomized study. | Zhu M et al. | β | 2024 | β |
| Comprehensive mendelian randomization reveals atrial fibrillation-breast cancer relationship and explores common druggable targets. | Qi F et al. | β | 2024 | β |
| Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia. | Reus LM et al. | β | 2024 | β |
| Cross-population applications of genomics to understand the risk of multifactorial traits involving inflammation and immunity. | Alamad B et al. | β | 2024 | β |
| Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications. | Duffy Γ et al. | β | 2024 | β |
| Disease coverage of human genome-wide association studies and pharmaceutical research and development. | Gordillo-MaraΓ±Γ³n M et al. | β | 2024 | β |
| Disease progression strikingly differs in research and real-world Parkinson's populations. | Beaulieu-Jones BK et al. | β | 2024 | β |
| Drug development advances in human genetics-based targets. | Zhang X et al. | β | 2024 | β |
| Druggable targets for Parkinson's disease: transcriptomics based Mendelian randomization study. | Lyu Q et al. | β | 2024 | β |
| Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis. | Pirola CJ et al. | β | 2024 | β |
| Drug repurposing opportunities for chronic kidney disease. | Chen X et al. | β | 2024 | β |
| Drug risks associated with sarcopenia: a real-world and GWAS study. | Zhang Z et al. | β | 2024 | β |
| Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of AΞ² amyloidosis. | Kim B et al. | β | 2024 | β |
| Elevated Blood Pressure: A Genetically Determined Risk Factor for Cerebral Artery Dissection. | Xu X et al. | β | 2024 | β |
| eQTLs identify regulatory networks and drivers of variation in the individual response to sepsis. | Burnham KL et al. | β | 2024 | β |
| Evaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease. | Sharma P et al. | β | 2024 | β |
| Evolution and advancements in genomics and epigenomics in OA research: How far we have come. | Ramos YFM et al. | β | 2024 | β |
| Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank. | Lassen FH et al. | β | 2024 | β |
| Exploration of potential novel drug targets for diabetic retinopathy by plasma proteome screening. | Yuan W et al. | β | 2024 | β |
| Exploring novel drug targets for atopic dermatitis through plasma proteome with genome. | Wu W et al. | β | 2024 | β |
| Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci. | Goode EC et al. | β | 2024 | β |
| From genetic associations to genes: methods, applications, and challenges. | Qi T et al. | β | 2024 | β |
| GAA/FGF14 ataxia: an ode to the phenotype-first approach. | Indelicato E et al. | β | 2024 | β |
| Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research. | Nuytemans K et al. | β | 2024 | β |
| Generalized genetic liability to substance use disorders. | Miller AP et al. | β | 2024 | β |
| Genetically Supported Drug Targets and Dental Traits: A Mendelian Randomization Study. | Liu L et al. | β | 2024 | β |
| Genetic analyses identify brain imaging-derived phenotypes associated with the risk of intracerebral hemorrhage. | Liu Y et al. | β | 2024 | β |
| Genetic and molecular architecture of complex traits. | Lappalainen T et al. | β | 2024 | β |
| Genetic association of lipid traits and lipid-related drug targets with normal tension glaucoma: a Mendelian randomization study for predictive preventive and personalized medicine. | Kang T et al. | β | 2024 | β |
| Genetic factors associated with reasons for clinical trial stoppage. | Razuvayevskaya O et al. | β | 2024 | β |
| Genetic insights into drug targets for sporadic Creutzfeldt-Jakob disease: Integrative multi-omics analysis. | Jiang D et al. | β | 2024 | β |
| Genetics of chronic respiratory disease. | Sayers I et al. | β | 2024 | β |
| Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update. | Sookoian S et al. | β | 2024 | β |
| Genome-wide Mendelian randomization identifies drugs associated with body height. | Xi L et al. | β | 2024 | β |
| Genome-wide Studies Reveal Genetic Risk Factors for Hepatic Fat Content. | Li Y et al. | β | 2024 | β |
| Genomic diversity improves disease discovery for all. | Williamson A et al. | β | 2024 | β |
| GETdb: A comprehensive database for genetic and evolutionary features of drug targets. | Zhang Q et al. | β | 2024 | β |
| GLP1R Gene Expression and Kidney Disease Progression. | Triozzi JL et al. | β | 2024 | β |
| GWAS and 3D chromatin mapping identifies multicancer risk genes associated with hormone-dependent cancers. | Rivera IS et al. | β | 2024 | β |
| GWAS breakthroughs: mapping the journey from one locus to 393 significant coronary artery disease associations. | Aherrahrou R et al. | β | 2024 | β |
| High-throughput identification of functional regulatory SNPs in systemic lupus erythematosus. | Wang Q et al. | β | 2024 | β |
| How to build the virtual cell with artificial intelligence: Priorities and opportunities. | Bunne C et al. | β | 2024 | β |
| How to translate genetic findings into clinical applications in spondyloarthritis? | Frison E et al. | β | 2024 | β |
| Human genetics and epigenetics of alcohol use disorder. | Zhou H et al. | β | 2024 | β |
| Human Genetics and Genomics for Drug Target Identification and Prioritization: Open Targets' Perspective. | McDonagh EM et al. | β | 2024 | β |
| Identification of drug targets for SjΓΆgren's syndrome: multi-omics Mendelian randomization and colocalization analyses. | Bai Y et al. | β | 2024 | β |
| Identification of Genetic Loci Associated With Intracerebral Hemorrhage Using a Multitrait Analysis Approach. | MuiΓ±o E et al. | β | 2024 | β |
| Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study. | Wang H et al. | β | 2024 | β |
| Identification of potential drug targets for amyotrophic lateral sclerosis by Mendelian randomization analysis based on brain and plasma proteomics. | Yang N et al. | β | 2024 | β |
| Identification of potential drug targets for insomnia by Mendelian randomization analysis based on plasma proteomics. | Yang N et al. | β | 2024 | β |
| Identification of Potential Drug Targets for Myopia Through Mendelian Randomization. | Qin Y et al. | β | 2024 | β |
| Identification of potential therapeutic targets for skin cutaneous melanoma on the basic of transcriptomics. | Shi F et al. | β | 2024 | β |
| Identifying genetic determinants of sarcopenia-related traits: a Mendelian randomization study of druggable genes. | Wu J et al. | β | 2024 | β |
| Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. | Pan Z et al. | β | 2024 | β |
| Innovate therapeutic targets for autoimmune diseases: insights from proteome-wide mendelian randomization and Bayesian colocalization. | Jin Q et al. | β | 2024 | β |
| Integrating genetic and proteomic data to elucidate the association between immune system and blood-brain barrier dysfunction with multiple sclerosis risk and severity. | Sun D et al. | β | 2024 | β |
| Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases. | Farbehi N et al. | β | 2024 | β |
| Integration of variant annotations using deep set networks boosts rare variant association testing. | Clarke B et al. | β | 2024 | β |
| Integrin signalling in joint development, homeostasis and osteoarthritis. | Miao MZ et al. | β | 2024 | β |
| Investigating potential drug targets for IgA nephropathy and membranous nephropathy through multi-queue plasma protein analysis: a Mendelian randomization study based on SMR and co-localization analysis. | Xu X et al. | β | 2024 | β |
| Investigating potential novel therapeutic targets and biomarkers for ankylosing spondylitis using plasma protein screening. | You W et al. | β | 2024 | β |
| Lessons From The Glaucoma Foundation Think Tank 2023: A Patient-Centric Approach to Glaucoma. | Harris A et al. | β | 2024 | β |
| Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies. | Lessard S et al. | β | 2024 | β |
| Leveraging Mendelian randomization to inform drug discovery and development for ischemic stroke. | Daghlas I et al. | β | 2024 | β |
| Low-frequency and rare genetic variants associated with rheumatoid arthritis risk. | Kronzer VL et al. | β | 2024 | β |
| Machine learning predicts cellular response to genetic perturbation. | β | β | 2024 | β |
| Mapping drug biology to disease genetics to discover drug impacts on the human phenome. | Habib M et al. | β | 2024 | β |
| Mapping the functional impact of non-coding regulatory elements in primary T cells through single-cell CRISPR screens. | Alda-Catalinas C et al. | β | 2024 | β |
| Mendelian randomization analysis of the brain, cerebrospinal fluid, and plasma proteome identifies potential drug targets for attention deficit hyperactivity disorder. | Zhang C et al. | β | 2024 | β |
| Mendelian Randomization and Cardiovascular Disease-Enabling Expert Readership. | Natarajan P et al. | β | 2024 | β |
| Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. | Zhu Y et al. | β | 2024 | β |
| Multi-omics Mendelian randomization integrating GWAS, eQTL, and mQTL data identified genes associated with breast cancer. | Zhang Z et al. | β | 2024 | β |
| Naringenin modulates oxidative stress and lipid metabolism: Insights from network pharmacology, mendelian randomization, and molecular docking. | Gao J et al. | β | 2024 | β |
| New Insights on the Therapeutic Potential of Runt-Related Transcription FactorΒ 2 for Osteoarthritis: Evidence from Mendelian Randomization. | Xie J et al. | β | 2024 | β |
| Novel genetic insight for psoriasis: integrative genome-wide analyses in 863Β 080 individuals and proteome-wide Mendelian randomization. | Liu S et al. | β | 2024 | β |
| Novel insight into the etiology of ischemic stroke gained by integrative multiome-wide association study. | Jung J et al. | β | 2024 | β |
| Novel therapeutic targets for primary open-angle glaucoma identified through multicenter proteome-wide mendelian randomization. | Yuan W et al. | β | 2024 | β |
| Oxytocin Receptor Polymorphism Is Associated With Sleep Apnea Symptoms. | Goto H et al. | β | 2024 | β |
| PharmGWAS: a GWAS-based knowledgebase for drug repurposing. | Kang H et al. | β | 2024 | β |
| Plasma Proteome-Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID-19. | Krishnamoorthy S et al. | β | 2024 | β |
| Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk. | Tran D et al. | β | 2024 | β |
| Posttranscriptional regulation of <i>FAN1</i> by miR-124-3p at rs3512 underlies onset-delaying genetic modification in Huntington's disease. | Kim KH et al. | β | 2024 | β |
| Potential drug targets for gastroesophageal reflux disease and Barrett's esophagus identified through Mendelian randomization analysis. | Lin YL et al. | β | 2024 | β |
| Precision Approaches to Chronic Obstructive Pulmonary Disease Management. | Moll M et al. | β | 2024 | β |
| Predicting transcriptional outcomes of novel multigene perturbations with GEARS. | Roohani Y et al. | β | 2024 | β |
| Prioritization of therapeutic targets for cancers using integrative multi-omics analysis. | Jin X et al. | β | 2024 | β |
| Prioritizing drug targets in systemic lupus erythematosus from a genetic perspective: a druggable genome-wide Mendelian randomization study. | Gao Y et al. | β | 2024 | β |
| Priority index for critical Covid-19 identifies clinically actionable targets and drugs. | Zhang Z et al. | β | 2024 | β |
| Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: a multicenter Mendelian randomization study. | Zou X et al. | β | 2024 | β |
| Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm. | Golledge J et al. | β | 2024 | β |
| Proteome- and Transcriptome-Wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia. | Ardissino M et al. | β | 2024 | β |
| Ras, RhoA, and vascular pharmacology in neurodevelopment and aging. | Nussinov R et al. | β | 2024 | β |
| Raynaud phenomenon: from GWAS to drug repurposing. | Herrick AL et al. | β | 2024 | β |
| Refining the impact of genetic evidence on clinical success. | Minikel EV et al. | β | 2024 | β |
| Regulatory landscape enrichment analysis (RLEA): a computational toolkit for non-coding variant enrichment and cell type prioritization. | Rosean S et al. | β | 2024 | β |
| Repurposing of biologics and biopharmaceuticals. | Israr J et al. | β | 2024 | β |
| Rodent genetically modified models of glaucoma. | Loo Y et al. | β | 2024 | β |
| Sequential immunotherapy: towards cures for autoimmunity. | RamΓrez-Valle F et al. | β | 2024 | β |
| Sex-dependent placental methylation quantitative trait loci provide insight into the prenatal origins of childhood onset traits and conditions. | Casazza W et al. | β | 2024 | β |
| Shared etiology of Mendelian and complex disease supports drug discovery. | Lalagkas PN et al. | β | 2024 | β |
| Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates. | Lalagkas PN et al. | β | 2024 | β |
| Small-molecule probe for IBD risk variant GPR65 I231L alters cytokine signaling networks through positive allosteric modulation. | Neale I et al. | β | 2024 | β |
| SMIM1 absence is associated with reduced energy expenditure and excess weight. | Stefanucci L et al. | β | 2024 | β |
| Stopped clinical trials give evidence for the value of genetics. | King E | β | 2024 | β |
| Strategies for translating proteomics discoveries into drug discovery for dementia. | Halder A et al. | β | 2024 | β |
| Systematic discovery of gene-environment interactions underlying the human plasma proteome in UK Biobank. | Hillary RF et al. | β | 2024 | β |
| Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for hyperemesis gravidarum. | Wang F et al. | β | 2024 | β |
| Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer. | Song W et al. | β | 2024 | β |
| Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy. | Ghodke-Puranik Y et al. | β | 2024 | β |
| TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro. | Duan QQ et al. | β | 2024 | β |
| The GPS for drug development: navigating with evidence from human populations. | Buergel TM et al. | β | 2024 | β |
| The landscape of the methodology in drug repurposing using human genomic data: a systematic review. | Wang L et al. | β | 2024 | β |
| Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses. | Luan Y et al. | β | 2024 | β |
| The Role of Genetics in Advancing Cardiometabolic Drug Development. | Abou-Karam R et al. | β | 2024 | β |
| Transcriptome-Wide Association Studies (TWAS): Methodologies, Applications, and Challenges. | Evans P et al. | β | 2024 | β |
| Transcriptome-wide Mendelian randomization during CD4<sup>+</sup> T cell activation reveals immune-related drug targets for cardiometabolic diseases. | Wu X et al. | β | 2024 | β |
| Trends in drug development for rare and intractable diseases based on the KEGG NETWORK. | Tanabe M et al. | β | 2024 | β |
| Tumor necrosis factor mediates the impact of PM<sub>2.5</sub> on bone mineral density: Inflammatory proteome Mendelian randomization and colocalization analyses. | Li M et al. | β | 2024 | β |
| Unspecified asthma, childhood-onset, and adult-onset asthma have different causal genes: a Mendelian randomization analysis. | Zaied RE et al. | β | 2024 | β |
| Unveiling new genetic insights in rheumatoid arthritis for drug discovery through Taxonomy3 analysis. | Kozlowska J et al. | β | 2024 | β |
| Unveiling novel genetic variants in 370 challenging medically relevant genes using the long read sequencing data of 41 samples from 19 global populations. | Ji Y et al. | β | 2024 | β |
| Unveiling potential drug targets for lung squamous cell carcinoma through the integration of druggable genome and genome-wide association data. | Wu W et al. | β | 2024 | β |
| Using genetics to investigate the association between lanosterol and cataract. | Hashimi M et al. | β | 2024 | β |
| Using Genomics to Identify Novel Therapeutic Targets for Aortic Disease. | Raghavan A et al. | β | 2024 | β |
| Using Mendelian randomization provides genetic insights into potential targets for sepsis treatment. | Xia R et al. | β | 2024 | β |
| Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization. | Guo X et al. | β | 2024 | β |
| 10Β Years of GWAS in intraocular pressure. | Gao XR et al. | β | 2023 | β |
| 23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function. | Fenaux J et al. | β | 2023 | β |
| A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis. | Manuel AM et al. | β | 2023 | β |
| A genomic deep field view of hypertension. | Garimella PS et al. | β | 2023 | β |
| AI/ML in Precision Medicine: A Look Beyond the Hype. | Xu Z et al. | β | 2023 | β |
| Alternative splicing in lung influences COVID-19 severity and respiratory diseases. | Nakanishi T et al. | β | 2023 | β |
| An Atlas of Variant Effects to understand the genome at nucleotide resolution. | Fowler DM et al. | β | 2023 | β |
| Applications of single-cell RNA sequencing in drug discovery and development. | Van de Sande B et al. | β | 2023 | β |
| A publication-wide association study (PWAS), historical language models to prioritise novel therapeutic drug targets. | Narganes-CarlΓ³n D et al. | β | 2023 | β |
| Association between human blood metabolome and the risk of breast cancer. | Wang Y et al. | β | 2023 | β |
| Association Between Human Blood Metabolome and the Risk of Psychiatric Disorders. | Jia Y et al. | β | 2023 | β |
| Association between Neuroligin-1 polymorphism and plasma glutamine levels in individuals with autism spectrum disorder. | Lee IH et al. | β | 2023 | β |
| Association Between Prekallikrein and Stroke: A Mendelian Randomization Study. | Wang Y et al. | β | 2023 | β |
| Association of asthma genetic variants with asthma-associated traits reveals molecular pathways ofΒ eosinophilic asthma. | El-Husseini ZW et al. | β | 2023 | β |
| A systems biology approach identifies the role of dysregulated PRDM6 in the development of hypertension. | Gunawardhana KL et al. | β | 2023 | β |
| Biological and functional multimorbidity-from mechanisms to management. | Langenberg C et al. | β | 2023 | β |
| Causal inference in drug discovery and development. | Michoel T et al. | β | 2023 | β |
| Circulating sphingolipids in heart failure. | Kovilakath A et al. | β | 2023 | β |
| Complex effects of sequence variants on lipid levels and coronary artery disease. | Snaebjarnarson AS et al. | β | 2023 | β |
| Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis. | Brown AC et al. | β | 2023 | β |
| Converging evidence from exome sequencing and common variants implicates target genes for osteoporosis. | Zhou S et al. | β | 2023 | β |
| COVID-19 host genetics and ABO blood group susceptibility. | Ellinghaus D | β | 2023 | β |
| CRISPR screens identify gene targets at breast cancer risk loci. | Tuano NK et al. | β | 2023 | β |
| DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases. | Rakicevic L | β | 2023 | β |
| Epigenetics as a mediator of genetic risk in osteoarthritis: role during development, homeostasis, aging, and disease progression. | Richard D et al. | β | 2023 | β |
| Examining the shared etiology of psychopathology with genome-wide association studies. | Mallard TT et al. | β | 2023 | β |
| Expanding causal genes for Parkinson's disease via multi-omics analysis. | Gu XJ et al. | β | 2023 | β |
| From function to translation: Decoding genetic susceptibility to human diseases via artificial intelligence. | Long E et al. | β | 2023 | β |
| From target discovery to clinical drug development with human genetics. | Trajanoska K et al. | β | 2023 | β |
| Future prospects for human genetics and genomics in drug discovery. | Ghoussaini M et al. | β | 2023 | β |
| Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk. | Harlow CE et al. | β | 2023 | β |
| Genetic and Gene Expression Resources for Osteoporosis and Bone Biology Research. | Kaya S et al. | β | 2023 | β |
| Genetic and molecular biomarkers for geographic atrophy. | Riley-Gillis B et al. | β | 2023 | β |
| Genetic Determinants of the Acute Respiratory Distress Syndrome. | Suarez-Pajes E et al. | β | 2023 | β |
| Genetic Insights on the Relation ofΒ Vascular Risk Factors and CervicalΒ Artery Dissection. | Le Grand Q et al. | β | 2023 | β |
| Genetic modifiers of synucleinopathies-lessons from experimental models. | Lee RMQ et al. | β | 2023 | β |
| Genetics of migraine: Delineation of contemporary understanding of the genetic underpinning of migraine. | de Boer I et al. | β | 2023 | β |
| Genetics of varicose veins reveals polygenic architecture and genetic overlap with arterial and venous disease. | Levin MG et al. | β | 2023 | β |
| Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. | Kiryluk K et al. | β | 2023 | β |
| Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. | Liu J et al. | β | 2023 | β |
| Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment. | Li C et al. | β | 2023 | β |
| Genomic map of inflammatory blood proteins. | β | β | 2023 | β |
| Germline mechanisms of immunotherapy toxicities in the era of genome-wide association studies. | Gusev A | β | 2023 | β |
| GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study. | Ueda M et al. | β | 2023 | β |
| Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery. | Krebs K et al. | β | 2023 | β |
| HDAC9 Inhibition as a Novel Treatment for Stroke. | Markus HS | β | 2023 | β |
| Healthy lifestyle? or just the right genetic mutations. | Butera A et al. | β | 2023 | β |
| Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort. | Pu A et al. | β | 2023 | β |
| Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study. | Cao Y et al. | β | 2023 | β |
| Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses. | Zhang N et al. | β | 2023 | β |
| Identifying Genes Associated with Alzheimer's Disease Using Gene-Based Polygenic Risk Score. | Lai D et al. | β | 2023 | β |
| Idiopathic pulmonary fibrosis. | Koudstaal T et al. | β | 2023 | β |
| Large-scale multitrait genome-wide association analyses identify hundreds of glaucoma risk loci. | Han X et al. | β | 2023 | β |
| Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study. | Allen RJ et al. | β | 2023 | β |
| Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPARΞ³ signaling. | Schuermans N et al. | β | 2023 | β |
| Male-pattern hair loss: Comprehensive identification of the associated genes as a basis for understanding pathophysiology. | Henne SK et al. | β | 2023 | β |
| Mendelian randomization as a tool to inform drug development using human genetics. | Daghlas I et al. | β | 2023 | β |
| Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders. | Li X et al. | β | 2023 | β |
| Molecular Landscape of Tourette's Disorder. | Widomska J et al. | β | 2023 | β |
| Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals. | Zhou H et al. | β | 2023 | β |
| Multi-layered genetic approaches to identify approved drug targets. | Sadler MC et al. | β | 2023 | β |
| Multiomic Analysis and CRISPR Perturbation Screens Identify Endothelial Cell Programs and Novel Therapeutic Targets for Coronary Artery Disease. | Gupta RM et al. | β | 2023 | β |
| Multi-omics in Crohn's disease: New insights from inside. | Mu C et al. | β | 2023 | β |
| Multi-omic underpinnings of epigenetic aging and human longevity. | Mavromatis LA et al. | β | 2023 | β |
| Network expansion of genetic associations defines a pleiotropy map of human cell biology. | Barrio-Hernandez I et al. | β | 2023 | β |
| New "drugs and targets" in the GWAS era of bipolar disorder. | Qi HX et al. | β | 2023 | β |
| New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. | Andreassen OA et al. | β | 2023 | β |
| Novel Functional Genomics Approaches Bridging Neuroscience and Psychiatry. | Restrepo-Lozano JM et al. | β | 2023 | β |
| Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis. | Lorefice L et al. | β | 2023 | β |
| On the way to translate GWAS into kidney disease mechanisms. | Devuyst O et al. | β | 2023 | β |
| otargen: GraphQL-based R package for tidy data accessing and processing from Open Targets Genetics. | Feizi A et al. | β | 2023 | β |
| Pharmacogenomics: current status and future perspectives. | Pirmohamed M | β | 2023 | β |
| Plasma proteomic associations with genetics and health in the UK Biobank. | Sun BB et al. | β | 2023 | β |
| Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease. | Mazidi M et al. | β | 2023 | β |
| Potential drug targets for asthma identified in the plasma and brain through Mendelian randomization analysis. | Wang Y et al. | β | 2023 | β |
| Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. | Lin J et al. | β | 2023 | β |
| Precision medicine for cardiometabolic disease: a framework for clinical translation. | Franks PW et al. | β | 2023 | β |
| Precision medicine in systemic lupus erythematosus. | Fasano S et al. | β | 2023 | β |
| Predicting ExWAS findings from GWAS data: a shorter path to causal genes. | Liang KYH et al. | β | 2023 | β |
| Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood. | Ge YJ et al. | β | 2023 | β |
| Prioritization of genes associated with type 2 diabetes mellitus for functional studies. | Tan WX et al. | β | 2023 | β |
| Priority index for asthma (PIA): In silico discovery of shared and distinct drug targets for adult- and childhood-onset disease. | Bao C et al. | β | 2023 | β |
| Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms. | Pividori M et al. | β | 2023 | β |
| Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases. | Carland C et al. | β | 2023 | β |
| Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism. | Hassan N et al. | β | 2023 | β |
| Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study. | Qin C et al. | β | 2023 | β |
| Shared genetic loci between Alzheimer's disease and multiple sclerosis: Crossroads between neurodegeneration and immune system. | Fominykh V et al. | β | 2023 | β |
| Shared genetic risk factors: implications for treatment of idiopathic pulmonary fibrosis and systemic hypertension. | Parcesepe G et al. | β | 2023 | β |
| Single-cell genomics meets human genetics. | Cuomo ASE et al. | β | 2023 | β |
| Statistical methods for cis-Mendelian randomization with two-sample summary-level data. | Gkatzionis A et al. | β | 2023 | β |
| Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease. | Su WM et al. | β | 2023 | β |
| The common IL1A single nucleotide polymorphism rs17561 is a hypomorphic mutation that significantly reduces interleukin-1Ξ± release from human blood cells. | Wiggins KA et al. | β | 2023 | β |
| The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. | Yeo SC et al. | β | 2023 | β |
| The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. | Ochoa D et al. | β | 2023 | β |
| The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases. | Jurrjens AW et al. | β | 2023 | β |
| The role of clinical imaging in oncology drug development: progress and new challenges. | Murphy PS et al. | β | 2023 | β |
| The role of ion channels in the relationship between the immune system and cancer. | Erdogan MA et al. | β | 2023 | β |
| TIE1 and TEK signalling, intraocular pressure, and primary open-angle glaucoma: a Mendelian randomization study. | Rajasundaram S et al. | β | 2023 | β |
| TYK2 as a novel therapeutic target in psoriasis. | Elyoussfi S et al. | β | 2023 | β |
| Unlocking the Medicinal Mysteries: Preventing Lacunar Stroke with Drug Repurposing. | Zhang L et al. | β | 2023 | β |
| Use of big data and machine learning algorithms to extract possible treatment targets in neurodevelopmental disorders. | Malik MA et al. | β | 2023 | β |
| Using genetic association data to guide drug discovery and development: Review of methods and applications. | Burgess S et al. | β | 2023 | β |
| Using human genetics to improve safety assessment of therapeutics. | Carss KJ et al. | β | 2023 | β |
| Validation of Artificial Intelligence Containing Products Across the Regulated Healthcare Industries. | Higgins DC et al. | β | 2023 | β |
| Wrestling with Social and Behavioral Genomics: Risks, Potential Benefits, and Ethical Responsibility. | Meyer MN et al. | β | 2023 | β |
| A conditional gene-based association framework integrating isoform-level eQTL data reveals new susceptibility genes for schizophrenia. | Li X et al. | β | 2022 | β |
| A cross-species approach using an inΒ vivo evaluation platform in mice demonstrates that sequence variation in human RABEP2 modulates ischemic stroke outcomes. | Lee HK et al. | β | 2022 | β |
| A functional <i>TGFB1</i> polymorphism in the donor associates with long-term graft survival after kidney transplantation. | Poppelaars F et al. | β | 2022 | β |
| AI for drug discovery is advancing rapidly: We need smart biology for it to fulfill its mission. | Ushio M et al. | β | 2022 | β |
| A Mendelian randomization study investigating the causal role of inflammation on Parkinson's disease. | Bottigliengo D et al. | β | 2022 | β |
| A multiple sclerosis-protective coding variant reveals an essential role for HDAC7 in regulatory T cells. | Axisa PP et al. | β | 2022 | β |
| An effector index to predict target genes at GWAS loci. | Forgetta V et al. | β | 2022 | β |
| An interleukin 6-based genetic risk score strengthened with interleukin 10 polymorphisms associated with long-term kidney allograft outcomes. | Eskandari SK et al. | β | 2022 | β |
| A novel 'social contract' - An attempt to harmonize a sponsor's exploratory research with a clinical study participant's data rights. | Mignon L et al. | β | 2022 | β |
| An Overview of Methods and Exemplars of the Use of Mendelian Randomisation in Nutritional Research. | Bennett DA et al. | β | 2022 | β |
| Anticipating Pharmacological Perturbation With Human Genetic Variation-Lessons From CETP. | Natarajan P et al. | β | 2022 | β |
| A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. | Namba S et al. | β | 2022 | β |
| A resource for integrated genomic analysis of the human liver. | Zhou YH et al. | β | 2022 | β |
| Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease. | Fang J et al. | β | 2022 | β |
| Association between Human Blood Metabolome and the Risk of Alzheimer's Disease. | Sun L et al. | β | 2022 | β |
| A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. | Serelli-Lee V et al. | β | 2022 | β |
| Bridging the splicing gap in human genetics with long-read RNA sequencing: finding the protein isoform drivers of disease. | Castaldi PJ et al. | β | 2022 | β |
| Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery. | Simpson S et al. | β | 2022 | β |
| Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease. | Khani M et al. | β | 2022 | β |
| Clinical Utility of Genomic Testing in Cancer Care. | Pritchard D et al. | β | 2022 | β |
| Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease. | Nabirotchkin S et al. | β | 2022 | β |
| Coming of Age: Human Genomics and the Cancer-Immune Set Point. | Hammer C et al. | β | 2022 | β |
| Computational estimation of quality and clinical relevance of cancer cell lines. | Trastulla L et al. | β | 2022 | β |
| Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). | Bienfait K et al. | β | 2022 | β |
| Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. | Winkler TW et al. | β | 2022 | β |
| Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. | Mortberg MA et al. | β | 2022 | β |
| Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery. | Reddy DS et al. | β | 2022 | β |
| Drug repurposing candidates to treat core symptoms in autism spectrum disorder. | Koch E et al. | β | 2022 | β |
| DSEATM: drug set enrichment analysis uncovering disease mechanisms by biomedical text mining. | Luo ZH et al. | β | 2022 | β |
| Effects of Coronary Artery Disease-Associated Variants on Vascular Smooth Muscle Cells. | Solomon CU et al. | β | 2022 | β |
| Emerging therapeutic opportunities for integrin inhibitors. | Slack RJ et al. | β | 2022 | β |
| Evaluating a Causal Relationship between Complement Factor I Protein Level and Advanced Age-Related Macular Degeneration Using Mendelian Randomization. | Jones AV et al. | β | 2022 | β |
| Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study. | Zheng J et al. | β | 2022 | β |
| Exploiting gene dependency to inform drug development for multiple myeloma. | Went M et al. | β | 2022 | β |
| Fine mapping with epigenetic information and 3D structure. | Orozco G | β | 2022 | β |
| Functional interrogation of autoimmune disease genetics using CRISPR/Cas9 technologies and massively parallel reporter assays. | Ding J et al. | β | 2022 | β |
| Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models. | Kague E et al. | β | 2022 | β |
| Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans. | Lai D et al. | β | 2022 | β |
| Genetic associations of protein-coding variants in human disease. | Sun BB et al. | β | 2022 | β |
| Genetic determinants of fungi-induced ROS production are associated with the risk of invasive pulmonary aspergillosis. | Matzaraki V et al. | β | 2022 | β |
| Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease. | Gong J et al. | β | 2022 | β |
| Genetic Predisposition and the Variable Course of Infectious Diseases. | Schmidt A et al. | β | 2022 | β |
| Genetic regulation of RNA splicing in human pancreatic islets. | Atla G et al. | β | 2022 | β |
| Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. | Cho MH et al. | β | 2022 | β |
| Genetics of common cerebral small vessel disease. | Bordes C et al. | β | 2022 | β |
| Genetics of multiple sclerosis: lessons from polygenicity. | Goris A et al. | β | 2022 | β |
| Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. | Hautakangas H et al. | β | 2022 | β |
| Genomic Evidence Supports the Recognition of Endometriosis as an Inflammatory Systemic Disease and Reveals Disease-Specific Therapeutic Potentials of Targeting Neutrophil Degranulation. | Bao C et al. | β | 2022 | β |
| Germline Mutations in <i>CIDEB</i> and Protection against Liver Disease. | Verweij N et al. | β | 2022 | β |
| How genetic risk contributes to autoimmune liver disease. | Ellinghaus D | β | 2022 | β |
| How Genetics Can Improve Clinical Practice in Chronic Kidney Disease: From Bench to Bedside. | Piras D et al. | β | 2022 | β |
| Human Genomics and Drug Development. | Schmidt AF et al. | β | 2022 | β |
| Hypertension Pharmacogenomics in CKD: The Clinical Relevance and Public Health Implications. | Geng TT et al. | β | 2022 | β |
| Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies. | Harlow CE et al. | β | 2022 | β |
| Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. | Magdy T et al. | β | 2022 | β |
| Identification of human gene research articles with wrongly identified nucleotide sequences. | Park Y et al. | β | 2022 | β |
| Identifying Genetic Variants and Metabolites Associated with Rapid Estimated Glomerular Filtration Rate Decline in Korea Based on Genome-Metabolomic Integrative Analysis. | Lee S et al. | β | 2022 | β |
| Identifying novel proteins underlying schizophrenia via integrating pQTLs of the plasma, CSF, and brain with GWAS summary data. | Gu X et al. | β | 2022 | β |
| Immune disease variants modulate gene expression in regulatory CD4<sup>+</sup> TΒ cells. | Bossini-Castillo L et al. | β | 2022 | β |
| Immune targets for therapeutic development in depression: towards precision medicine. | Drevets WC et al. | β | 2022 | β |
| Improving mouse models for the study of Alzheimer's disease. | Reagan AM et al. | β | 2022 | β |
| Inhibiting thyroid activation in aged human explants prevents mechanical induced detrimental signalling by mitigating metabolic processes. | Houtman E et al. | β | 2022 | β |
| Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. | Wu P et al. | β | 2022 | β |
| Integration of GWAS and brain transcriptomic analyses in a multiethnic sample of 35,245 older adults identifies DCDC2 gene as predictor of episodic memory maintenance. | Gao Y et al. | β | 2022 | β |
| Integration of innovative statistical methods using genetic data provides pharmacological insight and facilitates drug development. | Grant AJ | β | 2022 | β |
| Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. | Truong TTT et al. | β | 2022 | β |
| Integrative analysis of 3604 GWAS reveals multiple novel cell type-specific regulatory associations. | Breeze CE et al. | β | 2022 | β |
| Integrative multi-omics database (iMOMdb) of Asian pregnant women. | Pan H et al. | β | 2022 | β |
| Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease. | Xu J et al. | β | 2022 | β |
| Intersecting single-cell transcriptomics and genome-wide association studies identifies crucial cell populations and candidate genes for atherosclerosis. | Slenders L et al. | β | 2022 | β |
| Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. | Sazonovs A et al. | β | 2022 | β |
| Loss of Sucrase-Isomaltase Function Increases Acetate Levels and Improves Metabolic Health in Greenlandic Cohorts. | Andersen MK et al. | β | 2022 | β |
| Mendelian Randomization: Concepts and Scope. | Richmond RC et al. | β | 2022 | β |
| Molecular genetics of cocaine use disorders in humans. | FernΓ ndez-Castillo N et al. | β | 2022 | β |
| Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. | Akbari P et al. | β | 2022 | β |
| Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity. | Zheng J et al. | β | 2022 | β |
| Multi-modality machine learning predicting Parkinson's disease. | Makarious MB et al. | β | 2022 | β |
| Multi-omics research in sarcopenia: Current progress and future prospects. | Liu JC et al. | β | 2022 | β |
| Network analysis of genome-wide association studies for drug target prioritisation. | Barrio-Hernandez I et al. | β | 2022 | β |
| Network-Driven Drug Discovery. | Wray J et al. | β | 2022 | β |
| Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias. | Yu L et al. | β | 2022 | β |
| Optimizing Translational Research for Exceptional Health and Life Span: A Systematic Narrative of Studies to Identify Translatable Therapeutic Target(s) for Exceptional Health Span in Humans. | Raghavachari N et al. | β | 2022 | β |
| Organization of gene programs revealed by unsupervised analysis of diverse gene-trait associations. | Mizikovsky D et al. | β | 2022 | β |
| Pharmacogenomics for the efficacy and side effects of antihistamines. | Li L et al. | β | 2022 | β |
| Pharmacogenomics: Relevance and opportunities for clinical pharmacology. | Turner RM et al. | β | 2022 | β |
| PiER: web-based facilities tailored for genetic target prioritisation harnessing human disease genetics, functional genomics and protein interactions. | Fang H | β | 2022 | β |
| Polygenic risk scores: An overview from bench to bedside for personalised medicine. | Cross B et al. | β | 2022 | β |
| Predictive validity in drug discovery: what it is, why it matters and how to improve it. | Scannell JW et al. | β | 2022 | β |
| Pregnancy, preeclampsia and maternal aging: From epidemiology to functional genomics. | Miller EC et al. | β | 2022 | β |
| Priority index: database of genetic targets in immune-mediated disease. | Fang H et al. | β | 2022 | β |
| Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. | AgΓΌera-Ortiz L et al. | β | 2022 | β |
| Putative Candidate Drug Targets for Sarcopenia-Related Traits Identified Through Mendelian Randomization Analysis of the Blood Proteome. | Chen BB et al. | β | 2022 | β |
| Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation. | Wang G et al. | β | 2022 | β |
| Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity. | Deaton AM et al. | β | 2022 | β |
| Research Priorities for Kidney-Related Research-An Agenda to Advance Kidney Care: A Position Statement From the National Kidney Foundation. | National Kidney Foundation Research Roundtable Work Group on behalf of the National Kidney Foundation | β | 2022 | β |
| Scalable approaches for functional analyses of whole-genome sequencing non-coding variants. | Kuksa PP et al. | β | 2022 | β |
| Short structural variants as informative genetic markers for ALS disease risk and progression. | Theunissen F et al. | β | 2022 | β |
| Stroke Genetics: Discovery, Insight Into Mechanisms, and Clinical Perspectives. | Debette S et al. | β | 2022 | β |
| Target Discovery for Drug Development Using Mendelian Randomization. | Evans DS | β | 2022 | β |
| Ten challenges for clinical translation in psychiatric genetics. | Derks EM et al. | β | 2022 | β |
| The characteristics of early-stage research into human genes are substantially different from subsequent research. | Stoeger T et al. | β | 2022 | β |
| The genetic basis for adult onset glaucoma: Recent advances and future directions. | Wang Z et al. | β | 2022 | β |
| The genetic overlap between osteoporosis and craniosynostosis. | Kague E et al. | β | 2022 | β |
| The grand challenge of discovering new cardiovascular drugs. | Hong CC | β | 2022 | β |
| The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases. | Alsheikh AJ et al. | β | 2022 | β |
| The module triad: a novel network biology approach to utilize patients' multi-omics data for target discovery in ulcerative colitis. | Voitalov I et al. | β | 2022 | β |
| The role of gene-ambient air pollution interactions in paediatric asthma. | Kelchtermans J et al. | β | 2022 | β |
| Translating osteoarthritis genetics research: challenging times ahead. | Loughlin J | β | 2022 | β |
| Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics. | Montero-Melendez T et al. | β | 2022 | β |
| Tumor Necrosis Factor-Ξ± Gene Polymorphism is Associated with Short- and Long-Term Kidney Allograft Outcomes. | Poppelaars F et al. | β | 2022 | β |
| Using causal methods to map symptoms to brain circuits in neurodevelopment disorders: moving from identifying correlates to developing treatments. | Cohen AL | β | 2022 | β |
| Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100. | Park BJ et al. | β | 2022 | β |
| VannoPortal: multiscale functional annotation of human genetic variants for interrogating molecular mechanism of traits and diseases. | Huang D et al. | β | 2022 | β |
| Whole-exome sequencing study identifies rare variants and genes associated with intraocular pressure and glaucoma. | Gao XR et al. | β | 2022 | β |
| 10Β K: a large-scale prospective longitudinal study in Israel. | Shilo S et al. | β | 2021 | β |
| A catalog of GWAS fine-mapping efforts in autoimmune disease. | Caliskan M et al. | β | 2021 | β |
| A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment. | Xu F et al. | β | 2021 | β |
| Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. | Gaziano L et al. | β | 2021 | β |
| Activity- and reactivity-based proteomics: Recent technological advances and applications in drug discovery. | Benns HJ et al. | β | 2021 | β |
| Advances in microfluidic in vitro systems for neurological disease modeling. | Holloway PM et al. | β | 2021 | β |
| Advancing drug discovery using the power of the human genome. | Heilbron K et al. | β | 2021 | β |
| Advancing the use of genome-wide association studies for drug repurposing. | Reay WR et al. | β | 2021 | β |
| A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. | Foley CN et al. | β | 2021 | β |
| AI models and the future of genomic research and medicine: True sons of knowledge?: Artificial intelligence needs to be integrated with causal conceptions in biomedicine to harness its societal benefits for the field. | KΓΆnig H et al. | β | 2021 | β |
| A KCNK16 mutation causing TALK-1 gain of function is associated with maturity-onset diabetes of the young. | Graff SM et al. | β | 2021 | β |
| An Academic Clinician's Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX. | Magavern EF et al. | β | 2021 | β |
| A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. | Zhou S et al. | β | 2021 | β |
| An integrative network-based approach for drug target indication expansion. | Han Y et al. | β | 2021 | β |
| An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. | Mountjoy E et al. | β | 2021 | β |
| Anti-Irritant Strategy against Retinol Based on the Genetic Analysis of Korean Population: A Genetically Guided Top-Down Approach. | Kang S et al. | β | 2021 | β |
| An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. | Pan Z et al. | β | 2021 | β |
| Approval success rates of drug candidates based on target, action, modality, application, and their combinations. | Yamaguchi S et al. | β | 2021 | β |
| Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development. | Santus E et al. | β | 2021 | β |
| Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. | Bender A et al. | β | 2021 | β |
| Assessing the Function of the <i>ZFP90</i> Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes. | Zhu T et al. | β | 2021 | β |
| Association of Antihypertensive Drug Target Genes With Psychiatric Disorders: A Mendelian Randomization Study. | Chauquet S et al. | β | 2021 | β |
| A trans-omic Mendelian randomization study of parental lifespan uncovers novel aging biology and therapeutic candidates for chronic diseases. | Perrot N et al. | β | 2021 | β |
| A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. | DΓaz-Caneja CM et al. | β | 2021 | β |
| Challenges and Opportunities in Understanding Genetics of Fungal Diseases: Towards a Functional Genomics Approach. | Bruno M et al. | β | 2021 | β |
| Chemogenomics for drug discovery: clinical molecules from open access chemical probes. | Quinlan RBA et al. | β | 2021 | β |
| Clinical Functional Genomics. | Carpenter S et al. | β | 2021 | β |
| Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms. | LΓ³pez-Isac E et al. | β | 2021 | β |
| Combining Human Genetics of Multiple Sclerosis with Oxidative Stress Phenotype for Drug Repositioning. | Olla S et al. | β | 2021 | β |
| Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. | Qin S et al. | β | 2021 | β |
| Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. | Metwally M et al. | β | 2021 | β |
| CRISPR-Cas9 in cancer therapeutics. | Randhawa S | β | 2021 | β |
| dbTMM: an integrated database of large-scale cohort, genome and clinical data for the Tohoku Medical Megabank Project. | Ogishima S et al. | β | 2021 | β |
| Deletion of <i>Abi3</i> gene locus exacerbates neuropathological features of Alzheimer's disease in a mouse model of AΞ² amyloidosis. | Karahan H et al. | β | 2021 | β |
| Dissecting polygenic signals from genome-wide association studies on human behaviour. | Abdellaoui A et al. | β | 2021 | β |
| Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation. | Poppelaars F et al. | β | 2021 | β |
| Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. | Fabbri C et al. | β | 2021 | β |
| Drug repurposing for cancer therapy, easier said than done. | Gonzalez-Fierro A et al. | β | 2021 | β |
| Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. | Heitsch L et al. | β | 2021 | β |
| Efficacy of computational predictions of the functional effect of idiosyncratic pharmacogenetic variants. | McConnell H et al. | β | 2021 | β |
| Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. | Fang J et al. | β | 2021 | β |
| Enhancers in disease: molecular basis and emerging treatment strategies. | Claringbould A et al. | β | 2021 | β |
| Estimating colocalization probability from limited summary statistics. | King EA et al. | β | 2021 | β |
| Expanding the drug discovery space with predicted metabolite-target interactions. | Nuzzo A et al. | β | 2021 | β |
| Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome. | Unterman I et al. | β | 2021 | β |
| Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. | Dangond F et al. | β | 2021 | β |
| Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. | Storm CS et al. | β | 2021 | β |
| Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. | Robertson CC et al. | β | 2021 | β |
| From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery. | Nancy Z et al. | β | 2021 | β |
| From variant to function in human disease genetics. | Lappalainen T et al. | β | 2021 | β |
| Gene-level analysis of rare variants in 379,066 whole exome sequences identifies an association of GIGYF1 loss of function with type 2 diabetes. | Deaton AM et al. | β | 2021 | β |
| Genetic ablation of Gpnmb does not alter synuclein-related pathology. | Brendza R et al. | β | 2021 | β |
| Genetic Investigation of Inverse Psoriasis. | GΓΆblΓΆs A et al. | β | 2021 | β |
| Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | Bianco C et al. | β | 2021 | β |
| Genetic Prioritization, Therapeutic Repositioning and Cross-Disease Comparisons Reveal Inflammatory Targets Tractable for Kidney Stone Disease. | Fang H et al. | β | 2021 | β |
| Genetics and Epigenetics in Allergic Rhinitis. | Choi BY et al. | β | 2021 | β |
| Genetics of eating disorders in the genome-wide era. | Watson HJ et al. | β | 2021 | β |
| Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. | Hosking L et al. | β | 2021 | β |
| Genetic Susceptibility to Pneumonia: A GWAS Meta-Analysis Between the UK Biobank and FinnGen. | Campos AI et al. | β | 2021 | β |
| Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury. | Hakim A et al. | β | 2021 | β |
| Genome editing to define the function of risk loci and variants in rheumatic disease. | Baglaenko Y et al. | β | 2021 | β |
| Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. | Eijsbouts C et al. | β | 2021 | β |
| Genome-wide association of phenotypes based on clustering patterns of hand osteoarthritis identify <i>WNT9A</i> as novel osteoarthritis gene. | Boer CG et al. | β | 2021 | β |
| Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. | Yang C et al. | β | 2021 | β |
| Genomics-driven drug discovery based on disease-susceptibility genes. | Sonehara K et al. | β | 2021 | β |
| Genomics of hypertension: the road to precision medicine. | Padmanabhan S et al. | β | 2021 | β |
| Growth Factors and Their Roles in Multiple Sclerosis Risk. | Lu H et al. | β | 2021 | β |
| GW-SEM 2.0: Efficient, Flexible, and Accessible Multivariate GWAS. | Pritikin JN et al. | β | 2021 | β |
| Host genetics and infectious disease: new tools, insights and translational opportunities. | Kwok AJ et al. | β | 2021 | β |
| Human genome diversity data reveal that L564P is the predominant TPC2 variant and a prerequisite for the blond hair associated M484L gain-of-function effect. | BΓΆck J et al. | β | 2021 | β |
| Human inducible pluripotent stem cells: Realization of initial promise in drug discovery. | Kleiman RJ et al. | β | 2021 | β |
| Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation. | Brouwers B et al. | β | 2021 | β |
| Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. | Quinn MCJ et al. | β | 2021 | β |
| Identification of Novel Genomic-Variant Patterns of OR56A5, OR52L1, and CTSD in Retinitis Pigmentosa Patients by Whole-Exome Sequencing. | Lin TY et al. | β | 2021 | β |
| Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. | Baird DA et al. | β | 2021 | β |
| Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline. | Bui A et al. | β | 2021 | β |
| Identifying therapeutic drug targets using bidirectional effect genes. | Estrada K et al. | β | 2021 | β |
| Implications of genetic variation in the complement system in age-related macular degeneration. | de Jong S et al. | β | 2021 | β |
| Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. | JimΓ©nez-Kaufmann A et al. | β | 2021 | β |
| Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response. | Nguyen PBH et al. | β | 2021 | β |
| Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target. | Chen E et al. | β | 2021 | β |
| Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. | Holmes MV et al. | β | 2021 | β |
| Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates. | Konuma T et al. | β | 2021 | β |
| Integrative Network-Based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer Disease. | Gerring ZF et al. | β | 2021 | β |
| Integrative Neuroinformatics for Precision Prognostication and Personalized Therapeutics in Moderate and Severe Traumatic Brain Injury. | Zeiler FA et al. | β | 2021 | β |
| Large-scale sequencing studies expand the known genetic architecture of Alzheimer's disease. | Xue D et al. | β | 2021 | β |
| Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments. | Sheng X et al. | β | 2021 | β |
| Mendelian randomization for studying the effects of perturbing drug targets. | Gill D et al. | β | 2021 | β |
| Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target Validation. | Acosta JN et al. | β | 2021 | β |
| MendelVar: gene prioritization at GWAS loci using phenotypic enrichment of Mendelian disease genes. | Sobczyk MK et al. | β | 2021 | β |
| Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. | Gorski M et al. | β | 2021 | β |
| Multi-omics analyses of cognitive traits and psychiatric disorders highlights brain-dependent mechanisms. | Korologou-Linden R et al. | β | 2021 | β |
| Multi-tissue transcriptome-wide association study identifies eight candidate genes and tissue-specific gene expression underlying endometrial cancer susceptibility. | Kho PF et al. | β | 2021 | β |
| Multitrait GWAS to connect disease variants and biological mechanisms. | Julienne H et al. | β | 2021 | β |
| Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis. | Tapmeier TT et al. | β | 2021 | β |
| Novel characterization of the multivariate genetic architecture of internalizing psychopathology and alcohol use. | Colbert SMC et al. | β | 2021 | β |
| Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. | Ghoussaini M et al. | β | 2021 | β |
| Open Targets Platform: supporting systematic drug-target identification and prioritisation. | Ochoa D et al. | β | 2021 | β |
| Pairwise effects between lipid GWAS genes modulate lipid plasma levels and cellular uptake. | ZimoΕ M et al. | β | 2021 | β |
| Parameterized algorithms for identifying gene co-expression modules via weighted clique decomposition. | Cooley M et al. | β | 2021 | β |
| Perspective on Beyond Statistical Significance: Finding Meaningful Effects. | Edenberg HJ | β | 2021 | β |
| Perspectives on Drug Repurposing. | Schcolnik-Cabrera A et al. | β | 2021 | β |
| Photo-Switchable Sulfonylureas Binding to ATP-Sensitive Potassium Channel Reveal the Mechanism of Light-Controlled Insulin Release. | Walczewska-Szewc K et al. | β | 2021 | β |
| Platelet Glycoprotein Ib Ξ±-Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study. | Luo S et al. | β | 2021 | β |
| Precision Medicine Approaches to Vascular Disease: JACC Focus Seminar 2/5. | Miller CL et al. | β | 2021 | β |
| Predicting novel candidate human obesity genes and their site of action by systematic functional screening in Drosophila. | Agrawal N et al. | β | 2021 | β |
| Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. | Dwane L et al. | β | 2021 | β |
| Proteome-wide Systems Genetics to Identify Functional Regulators of Complex Traits. | Molendijk J et al. | β | 2021 | β |
| Rare variant contribution to human disease in 281,104 UK Biobank exomes. | Wang Q et al. | β | 2021 | β |
| Rare versus common diseases: a false dichotomy in precision medicine. | Chung BHY et al. | β | 2021 | β |
| Recent advances in lung cancer genomics: Application in targeted therapy. | Pathak N et al. | β | 2021 | β |
| Repurposing Cardio-Metabolic Drugs to Fight Covid19. | Battistoni A et al. | β | 2021 | β |
| Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. | Halloy F et al. | β | 2021 | β |
| Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. | Verstockt B et al. | β | 2021 | β |
| Revealing the role of the human blood plasma proteome in obesity using genetic drivers. | Zaghlool SB et al. | β | 2021 | β |
| Revisiting genome-wide association studies from statistical modelling to machine learning. | Sun S et al. | β | 2021 | β |
| Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. | Akbari P et al. | β | 2021 | β |
| Stroke Genetics: Turning Discoveries into Clinical Applications. | Dichgans M et al. | β | 2021 | β |
| Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. | Pietzner M et al. | β | 2021 | β |
| System Genetics Including Causal Inference Identify Immune Targets for Coronary Artery Disease and the Lifespan. | Bon-Baret V et al. | β | 2021 | β |
| Systems pharmacology approach uncovers Ligustilide attenuates experimental colitis in mice by inhibiting PPARΞ³-mediated inflammation pathways. | Huang Y et al. | β | 2021 | β |
| The evolution and history of gene editing technologies. | Randhawa S et al. | β | 2021 | β |
| The "GEnomics of Musculo Skeletal Traits TranslatiOnal NEtwork": Origins, Rationale, Organization, and Prospects. | Koromani F et al. | β | 2021 | β |
| The Interface of Therapeutics and Genomics in Cardiovascular Medicine. | Magavern EF et al. | β | 2021 | β |
| TiMEG: an integrative statistical method for partially missing multi-omics data. | Das S et al. | β | 2021 | β |
| Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. | Fabbri C et al. | β | 2021 | β |
| Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study. | Kang X et al. | β | 2021 | β |
| Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. | Zhu X et al. | β | 2021 | β |
| Understanding interactions between risk factors, and assessing the utility of the additive and multiplicative models through simulations. | Diaz-Gallo LM et al. | β | 2021 | β |
| Unique roles of rare variants in the genetics of complex diseases in humans. | Momozawa Y et al. | β | 2021 | β |
| Using Human Genetics to Understand Mechanisms in Ischemic Stroke Outcome: From Early Brain Injury to Long-Term Recovery. | Lee JM et al. | β | 2021 | β |
| Using Mendelian Randomization to Improve the Design of Randomized Trials. | Ference BA et al. | β | 2021 | β |
| Using "-omics" Data to Inform Genome-wide Association Studies (GWASs) in the Osteoporosis Field. | Abood A et al. | β | 2021 | β |
| Utilizing graph machine learning within drug discovery and development. | Gaudelet T et al. | β | 2021 | β |
| Workshop proceedings: GWAS summary statistics standards and sharing. | MacArthur JAL et al. | β | 2021 | β |
| A brief history of human disease genetics. | Claussnitzer M et al. | β | 2020 | β |
| A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. | Surakhy M et al. | β | 2020 | β |
| Adding value to real-world data: the role of biomarkers. | Plant D et al. | β | 2020 | β |
| Advances in Genomics for Drug Development. | Spreafico R et al. | β | 2020 | β |
| An Imperative Need for Further Genetic Studies of Alopecia Areata. | Petukhova L | β | 2020 | β |
| Approaching Shared Pathophysiology in Immune-Mediated Diseases through Functional Genomics. | GonzΓ‘lez-Serna D et al. | β | 2020 | β |
| A road map for understanding molecular and genetic determinants of osteoporosis. | Yang TL et al. | β | 2020 | β |
| A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. | Stampanoni Bassi M et al. | β | 2020 | β |
| A systems-level framework for anti-epilepsy drug discovery. | Johnson MR et al. | β | 2020 | β |
| A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome. | Richardson TG et al. | β | 2020 | β |
| A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. | Schneider RB et al. | β | 2020 | β |
| Axes of a revolution: challenges and promises of big data in healthcare. | Shilo S et al. | β | 2020 | β |
| Calcium Imaging in Drug Discovery for Psychiatric Disorders. | Seshadri S et al. | β | 2020 | β |
| Cerebral small vessel disease genomics and its implications across the lifespan. | Sargurupremraj M et al. | β | 2020 | β |
| Chances and challenges of machine learning-based disease classification in genetic association studies illustrated on age-related macular degeneration. | Guenther F et al. | β | 2020 | β |
| Characterizing the Causal Pathway for Genetic Variants Associated with Neurological Phenotypes Using Human Brain-Derived Proteome Data. | Kibinge NK et al. | β | 2020 | β |
| Comprehensive Analysis of the Genetic and Epigenetic Mechanisms of Osteoporosis and Bone Mineral Density. | Dong H et al. | β | 2020 | β |
| COVID-19 research risks ignoring important host genes due to pre-established research patterns. | Stoeger T et al. | β | 2020 | β |
| CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets. | Rubbini D et al. | β | 2020 | β |
| Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. | GonΓ§alves E et al. | β | 2020 | β |
| Evaluating drug targets through human loss-of-function genetic variation. | Minikel EV et al. | β | 2020 | β |
| From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. | Fang H et al. | β | 2020 | β |
| Functional investigation of the coronary artery disease gene SVEP1. | Winkler MJ et al. | β | 2020 | β |
| Functional studies of GWAS variants are gaining momentum. | Lichou F et al. | β | 2020 | β |
| Genetic architecture of common non-Alzheimer's disease dementias. | Guerreiro R et al. | β | 2020 | β |
| Genetic architecture of host proteins involved in SARS-CoV-2 infection. | Pietzner M et al. | β | 2020 | β |
| Genetics of Chronic Traumatic Encephalopathy. | Abdolmohammadi B et al. | β | 2020 | β |
| Genetics of COPD. | Silverman EK | β | 2020 | β |
| Genetics' Piece of the PI: Inferring the Origin of Complex Traits and Diseases from Proteome-Wide Protein-Protein Interaction Dynamics. | Gauthier L et al. | β | 2020 | β |
| Genetic underpinnings of cerebral edema in acute brain injury: an opportunity for pathway discovery. | Kirsch E et al. | β | 2020 | β |
| Genetic Variation and Response to Neurocritical Illness: a Powerful Approach to Identify Novel Pathophysiological Mechanisms and Therapeutic Targets. | Acosta JN et al. | β | 2020 | β |
| Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. | Allen RJ et al. | β | 2020 | β |
| Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology. | Bazaga A et al. | β | 2020 | β |
| Genome-wide pathogenesis interpretation using a heat diffusion-based systems genetics method and implications for gene function annotation. | Quan Y et al. | β | 2020 | β |
| Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. | Trajanoska K et al. | β | 2020 | β |
| Genomics-guided pre-clinical development of cancer therapies. | Francies HE et al. | β | 2020 | β |
| Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research. | Mealer RG et al. | β | 2020 | β |
| Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. | Fang J et al. | β | 2020 | β |
| Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability. | Asare Y et al. | β | 2020 | β |
| Identifying cross-disease components of genetic risk across hospital data in the UK Biobank. | Cortes A et al. | β | 2020 | β |
| Integrating Mouse and Human Genetic Data to Move beyond GWAS and Identify Causal Genes in Cholesterol Metabolism. | Li Z et al. | β | 2020 | β |
| Integrative genomics analysis of eQTL and GWAS summary data identifies PPP1CB as a novel bone mineral density risk genes. | Zhai Y et al. | β | 2020 | β |
| Leveraging genetic data to investigate molecular targets and drug repurposing candidates for treating alcohol use disorder and hepatotoxicity. | Gray JC et al. | β | 2020 | β |
| Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. | Jerome RN et al. | β | 2020 | β |
| Linking protein to phenotype with Mendelian Randomization detects 38 proteins with causal roles in human diseases and traits. | Bretherick AD et al. | β | 2020 | β |
| Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. | Nielsen JB et al. | β | 2020 | β |
| <i>ApoE</i> e2 and aging-related outcomes in 379,000 UK Biobank participants. | Kuo CL et al. | β | 2020 | β |
| Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. | Montaner J et al. | β | 2020 | β |
| Multiomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs. | Chen XF et al. | β | 2020 | β |
| Network and pathway expansion of genetic disease associations identifies successful drug targets. | MacNamara A et al. | β | 2020 | β |
| Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020. | Tobias JH et al. | β | 2020 | β |
| Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. | Zheng J et al. | β | 2020 | β |
| PhenomeXcan: Mapping the genome to the phenome through the transcriptome. | Pividori M et al. | β | 2020 | β |
| Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants. | Crouch DJM et al. | β | 2020 | β |
| Precision Medicine in Non-Communicable Diseases. | Novelli G et al. | β | 2020 | β |
| Psoriasis and Genetics. | Dand N et al. | β | 2020 | β |
| pyMeSHSim: an integrative python package for biomedical named entity recognition, normalization, and comparison of MeSH terms. | Luo ZH et al. | β | 2020 | β |
| Re-engineering CNS drug discovery and development using computer aided modeling. | Geerts H | β | 2020 | β |
| Repurposing of medications for pulmonary arterial hypertension. | Toshner M et al. | β | 2020 | β |
| RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice. | Karunakaran D et al. | β | 2020 | β |
| SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. | Bellucci G et al. | β | 2020 | β |
| Searching Far and Genome-Wide: The Relevance of Association Studies in Amyotrophic Lateral Sclerosis. | Rich KA et al. | β | 2020 | β |
| Strengthening Causal Inference for Complex Disease Using Molecular Quantitative Trait Loci. | Neumeyer S et al. | β | 2020 | β |
| Target discovery using biobanks and human genetics. | Hicks MA et al. | β | 2020 | β |
| The effect of LRRK2 loss-of-function variants in humans. | Whiffin N et al. | β | 2020 | β |
| The endless frontier? The recent increase of R&D productivity in pharmaceuticals. | Pammolli F et al. | β | 2020 | β |
| The Genetic Architecture of High Bone Mass. | Gregson CL et al. | β | 2020 | β |
| The genetics of asthma and the promise of genomics-guided drug target discovery. | El-Husseini ZW et al. | β | 2020 | β |
| The genetics of human ageing. | Melzer D et al. | β | 2020 | β |
| The Longevity-Associated SH2B3 (LNK) Genetic Variant: Selected Aging Phenotypes in 379,758 Subjects. | Kuo CL et al. | β | 2020 | β |
| The multiplex model of the genetics of Alzheimer's disease. | Sims R et al. | β | 2020 | β |
| 'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. | Swietlik EM et al. | β | 2020 | β |
| The road ahead in genetics and genomics. | McGuire AL et al. | β | 2020 | β |
| The role of genomics and genetics in pulmonary arterial hypertension. | Swietlik EM et al. | β | 2020 | β |
| The Role of Noncoding Variants in Heritable Disease. | French JD et al. | β | 2020 | β |
| The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs. | Cui H et al. | β | 2020 | β |
| The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. | Reilly DF et al. | β | 2020 | β |
| Tissue-specific genetic features inform prediction of drug side effects in clinical trials. | Duffy Γ et al. | β | 2020 | β |
| Transcriptome-wide association analysis offers novel opportunities for clinical translation of genetic discoveries on mental disorders. | Derks EM et al. | β | 2020 | β |
| Translational Genomics in Neurocritical Care: a Review. | Myserlis P et al. | β | 2020 | β |
| Turning genome-wide association study findings into opportunities for drug repositioning. | Lau A et al. | β | 2020 | β |
| Unravelling the complex genetics of common kidney diseases: from variants to mechanisms. | Sullivan KM et al. | β | 2020 | β |
| Update on NAFLD genetics: From new variants to the clinic. | TrΓ©po E et al. | β | 2020 | β |
| Using Mendelian randomization to understand and develop treatments for neurodegenerative disease. | Storm CS et al. | β | 2020 | β |
| Validity of the cold pressor test and pain sensitivity questionnaire via online self-administration. | McIntyre MH et al. | β | 2020 | β |
| Zebrafish models of sarcopenia. | Daya A et al. | β | 2020 | β |
| A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. | Wang Q et al. | β | 2019 | β |
| Adhesion G protein-coupled receptors: opportunities for drug discovery. | Bassilana F et al. | β | 2019 | β |
| A genetics-led approach defines the drug target landscape of 30 immune-related traits. | Fang H et al. | β | 2019 | β |
| Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. | Overend G et al. | β | 2019 | β |
| An atlas of genetic influences on osteoporosis in humans and mice. | Morris JA et al. | β | 2019 | β |
| A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome. | Misselbeck K et al. | β | 2019 | β |
| An exploratory phenome wide association study linking asthma and liver disease genetic variants to electronic health records from the Estonian Biobank. | James G et al. | β | 2019 | β |
| An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials. | Adeniyi O et al. | β | 2019 | β |
| Applications of machine learning in drug discovery and development. | Vamathevan J et al. | β | 2019 | β |
| Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. | King EA et al. | β | 2019 | β |
| A serum protein signature of APOE genotypes in centenarians. | Sebastiani P et al. | β | 2019 | β |
| Assessing drug target suitability using TargetMine | Chen Y et al. | β | 2019 | β |
| Assessing drug target suitability using TargetMine. | Chen YA et al. | β | 2019 | β |
| Atrial Fibrillation Genetics Update: Toward Clinical Implementation. | KalstΓΈ SM et al. | β | 2019 | β |
| Benchmarking network propagation methods for disease gene identification. | Picart-Armada S et al. | β | 2019 | β |
| Benefits and limitations of genome-wide association studies. | Tam V et al. | β | 2019 | β |
| Characterising the genetic basis of immune response variation to identify causal mechanisms underlying disease susceptibility. | Rotival M | β | 2019 | β |
| Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. | Martin P et al. | β | 2019 | β |
| Cohort Profile: Extended Cohort for E-health, Environment and DNA (EXCEED). | John C et al. | β | 2019 | β |
| Combined analysis of keratinocyte cancers identifies novel genome-wide loci. | Liyanage UE et al. | β | 2019 | β |
| Components of genetic associations across 2,138 phenotypes in the UK Biobank highlight adipocyte biology. | Tanigawa Y et al. | β | 2019 | β |
| Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. | Fontalis A et al. | β | 2019 | β |
| Deconstructing the sources of genotype-phenotype associations in humans. | Young AI et al. | β | 2019 | β |
| Development of Human Target Validation Classification that Predicts Future Clinical Efficacy. | Karlsson C et al. | β | 2019 | β |
| Discovery of common and rare genetic risk variants for colorectal cancer. | Huyghe JR et al. | β | 2019 | β |
| Dissecting the Genetics of Osteoporosis using Systems Approaches. | Al-Barghouthi BM et al. | β | 2019 | β |
| Editorial: Establishing Genetic Pleiotropy to Identify Common Pharmacological Agents for Common Diseases. | O'Mara TA et al. | β | 2019 | β |
| Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. | Farhan SMK et al. | β | 2019 | β |
| Genetic Insights for Drug Development in NAFLD. | Eslam M et al. | β | 2019 | β |
| Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. | Sakornsakolpat P et al. | β | 2019 | β |
| Genetics of Bone and Muscle Interactions in Humans. | Trajanoska K et al. | β | 2019 | β |
| Genetic Support for Longevity-Enhancing Drug Targets: Issues, Preliminary Data, and Future Directions. | McCorrison J et al. | β | 2019 | β |
| Genome-Wide Association Studies of Endometrial Cancer: Latest Developments and Future Directions. | O'Mara TA et al. | β | 2019 | β |
| Genome-wide association study of medication-use and associated disease in the UK Biobank. | Wu Y et al. | β | 2019 | β |
| Genome-wide meta-analysis reveals shared new <i>loci</i> in systemic seropositive rheumatic diseases. | Acosta-Herrera M et al. | β | 2019 | β |
| Genomic basis of delayed reward discounting. | Gray JC et al. | β | 2019 | β |
| Genomic Medicine-Progress, Pitfalls, and Promise. | Shendure J et al. | β | 2019 | β |
| GREP: genome for REPositioning drugs. | Sakaue S et al. | β | 2019 | β |
| GWAS and Beyond: Using Omics Approaches to Interpret SNP Associations. | Chen HH et al. | β | 2019 | β |
| GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. | LΓ³pez-Isac E et al. | β | 2019 | β |
| Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. | PΓΆlΓΆnen P et al. | β | 2019 | β |
| Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. | Lotta LA et al. | β | 2019 | β |
| Identifying and Validating New Drug Targets for Stroke and Beyond: Can Mendelian Randomization Help? | Plump A et al. | β | 2019 | β |
| Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. | Puccini A et al. | β | 2019 | β |
| Improving the odds of drug development success through human genomics: modelling study. | Hingorani AD et al. | β | 2019 | β |
| Integrating Mendelian randomization and multiple-trait colocalization to uncover cell-specific inflammatory drivers of autoimmune and atopic disease. | McGowan LM et al. | β | 2019 | β |
| Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. | Duarte Y et al. | β | 2019 | β |
| Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. | Glicksberg BS et al. | β | 2019 | β |
| Integrative analysis of vascular endothelial cell genomic features identifies AIDA as a coronary artery disease candidate gene. | Lalonde S et al. | β | 2019 | β |
| Interactome Analyses implicated CAMK2A in the genetic predisposition and pharmacological mechanism of Bipolar Disorder. | Li H et al. | β | 2019 | β |
| Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study. | Mokry LE et al. | β | 2019 | β |
| Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. | Wu D et al. | β | 2019 | β |
| Leveraging brain cortex-derived molecular data to elucidate epigenetic and transcriptomic drivers of complex traits and disease. | Hatcher C et al. | β | 2019 | β |
| Leveraging Genetic Findings for Precision Medicine in Vasculitis. | Acosta-Herrera M et al. | β | 2019 | β |
| Mapping causal pathways from genetics to neuropsychiatric disorders using genome-wide imaging genetics: Current status and future directions. | Le BD et al. | β | 2019 | β |
| MicroRNAs and regulation of cardiometabolic phenotypes: novel insights into the complexity of genome-wide association studies loci. | Civelek M et al. | β | 2019 | β |
| Moving from one to many: insights from the growing list of pleiotropic cancer risk genes. | Bien SA et al. | β | 2019 | β |
| New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. | Shrine N et al. | β | 2019 | β |
| Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome. | Chong M et al. | β | 2019 | β |
| PathFXweb: a web application for identifying drug safety and efficacy phenotypes. | Wilson JL et al. | β | 2019 | β |
| Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities. | Jhamb D et al. | β | 2019 | β |
| Pharmacogenes (PGx-genes): Current understanding and future directions. | Katara P et al. | β | 2019 | β |
| Pharmacogenetics and Depression: A Critical Perspective. | Corponi F et al. | β | 2019 | β |
| Pharmacogenomics. | Roden DM et al. | β | 2019 | β |
| Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. | Nguyen PA et al. | β | 2019 | β |
| PheWAS-Based Systems Genetics Methods for Anti-Breast Cancer Drug Discovery. | Gao M et al. | β | 2019 | β |
| Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians. | Rodrigues JCG et al. | β | 2019 | β |
| Post genome-wide association analysis: dissecting computational pathway/network-based approaches. | Chimusa ER et al. | β | 2019 | β |
| Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. | Lowe ME et al. | β | 2019 | β |
| Predicting clinically promising therapeutic hypotheses using tensor factorization. | Yao J et al. | β | 2019 | β |
| Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns. | Brommage R et al. | β | 2019 | β |
| Predicting translational progress in biomedical research. | Hutchins BI et al. | β | 2019 | β |
| Prioritizing target-disease associations with novel safety and efficacy scoring methods. | Failli M et al. | β | 2019 | β |
| Psychiatric Genetics Begins to Find Its Footing. | Smoller JW | β | 2019 | β |
| Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence. | Deaton AM et al. | β | 2019 | β |
| Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. | Costa Sa AC et al. | β | 2019 | β |
| Systems Chemical Genetics-Based Drug Discovery: Prioritizing Agents Targeting Multiple/Reliable Disease-Associated Genes as Drug Candidates. | Quan Y et al. | β | 2019 | β |
| Target 2035: probing the human proteome. | Carter AJ et al. | β | 2019 | β |
| The fog of genetics: what is known, unknown and unknowable in the genetics of complex traits and diseases. | de MagalhΓ£es JP et al. | β | 2019 | β |
| The genetic architecture of osteoporosis and fracture risk. | Trajanoska K et al. | β | 2019 | β |
| The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. | Buniello A et al. | β | 2019 | β |
| The ORMDL3 Asthma Gene Regulates ICAM1 and Has Multiple Effects on Cellular Inflammation. | Zhang Y et al. | β | 2019 | β |
| The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. | Acosta-Herrera M et al. | β | 2019 | β |
| The virtuous cycle of human genetics and mouse models in drug discovery. | Nadeau JH et al. | β | 2019 | β |
| Tissue-specific genes as an underutilized resource in drug discovery. | Ryaboshapkina M et al. | β | 2019 | β |
| Towards a Better Classification and Novel Therapies Based on the Genetics of Systemic Sclerosis. | Acosta-Herrera M et al. | β | 2019 | β |
| Translational genomics and precision medicine: Moving from the lab to the clinic. | Zeggini E et al. | β | 2019 | β |
| Update on the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond. | Kwon YC et al. | β | 2019 | β |
| Use of big data in drug development for precision medicine: an update. | Qian T et al. | β | 2019 | β |
| Using Human Genetics to Drive Drug Discovery: A Perspective. | Fox CS | β | 2019 | β |
| Using zebrafish to study skeletal genomics. | Kwon RY et al. | β | 2019 | β |
| All (animal) models (of neurodegeneration) are wrong. Are they also useful? | Ransohoff RM | β | 2018 | β |
| Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods. | Lv BM et al. | β | 2018 | β |
| ERS International Congress 2018: highlights from best-abstract awardees. | Burgy O et al. | β | 2018 | β |
| Leveraging Human Genetics to Guide Cancer Drug Development. | Kinnersley B et al. | β | 2018 | β |
| Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders. | Menke A | β | 2018 | β |
| Use of Mendelian <b>R</b>andomization for <b>I</b>dentifying <b>R</b>isk <b>F</b>actors for <b>B</b>rain <b>T</b>umors. | Howell AE et al. | β | 2018 | β |